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Blood vessel formation is critical throughout the life of vertebrate organisms, 
and vessel dysfunction jeopardizes both fetal development and adult survival.  
Diseases such as diabetes disrupt vessel regulation and contribute to numerous 
vascular pathologies.  Therefore, understanding blood vessel regulation in 
pathological conditions is essential to devising preventative treatments.  The 
work presented in this dissertation aims to understand how perturbations in the 
Ras activator, Ras guanyl-releasing protein 3 (RasGRP3), mediate aberrant 
vessel morphogenesis.  We have identified RasGRP3 as a downstream 
component in an endothelin-1 (ET1) signaling pathway.  ET1 signaling is a 
primary mediator of vascular pathology in diabetes.  I hypothesized that 
RasGRP3 mediates diabetes-induced embryopathy and changes in endothelial 
cell behavior and vessel morphology.  Work by Joanna Fried and Jessica Heinz 
demonstrated that RasGRP3 is required for embryogenesis in diabetic 
conditions.  In collaboration with Dr. Svetlana Rylova, I determined that activated 
RasGRP3 promotes Ras-ERK signaling, which can be induced by phorbol ester
iii  
or endothelin-1 (ET1). Dr. Rylova demonstrated that overexpression of activated 
RasGRP3 is sufficient to induce Ras-ERK activation and perturb directional 
migration.  In collaboration with Stephanie Kiser, I showed that RasGRP3 is 
required for ET1-induced Ras activation, proliferation and migration in endothelial 
cells.  Using an embryonic stem cell model to simulate pathological 
angiogenesis, we also identified a role for RasGRP3 in ET1-induced vessel 
dysmorphogenesis.  By identifying the molecular requirements that mediate 
RasGRP3-dependent effects, we can understand how changes in cellular or 
morphological processes induce vascular pathology.  The data herein advance 
our understanding of RasGRP3-vessel pathology as they may pertain to diabetic 
conditions. 
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A functional vasculature is essential for the development and survival of 
vertebrate organisms. Blood vessels form ordered, branched structures 
throughout the body to provide nutrients and remove waste from developing 
organs.  Leonardo da Vinci compared this branched network to a tree; he 
visualized the developing vasculature as sprouting from a seed (the heart) and 
forming a trunk (aorta, arteries) and roots (capillaries) 1. 
Signals regulating the formation and function of this highly ordered ‘tree’ are 
critical throughout the life of the organism, and in fact, vessel dysfunction 
jeopardizes both fetal development and adult survival.  In the adult, vessel 
dysfunction is associated with many cardiovascular diseases such as stroke, 
myocardial infarction, and peripheral vascular disease.  Because vessels deliver 
a blood supply to all areas of the body, perturbations in blood vessel formation 
can be detrimental to various organs and contribute to pathology in diseases 
such as cancer and diabetes.  Therefore, understanding blood vessel regulation 
in pathological conditions is essential to elucidate therapeutic targets. 
The work presented in this dissertation aims to understand how perturbations 
in a Ras activator mediate aberrant vessel morphogenesis.  We have identified 
the Ras activator, Ras guanyl-releasing protein 3 (RasGRP3), as a downstream 
component in an endothelin-1 (ET1) signaling pathway.  ET1 signaling 
contributes to vascular pathology in diabetes (reviews: 2-5).  We have also 
demonstrated that RasGRP3 is required to mediate diabetes-induced embryonic 
defects.  By identifying the molecular requirements that mediate RasGRP3-
dependent effects, we can understand how changes in cellular or morphological 
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processes induce vascular pathology.  The data herein advance our 
understanding of RasGRP3-vessel pathology as they may pertain to diabetic 
conditions. 
 
A.  Blood vessel formation.  Hypoxic tissues secrete growth factors, 
including Fibroblast-derived Growth Factor (FGF), angiopoetins, Platelet-derived 
Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), and Vascular 
Endothelial Growth Factor-A (VEGF), to stimulate blood vessel formation (6, 7 
reviews: 1, 8).  Blood vessel formation occurs by two sequential processes called 
vasculogenesis and angiogenesis.  Vasculogenesis is the process by which 
angioblasts, or endothelial progenitor cells derived from mesodermal tissue, 
differentiate into endothelial cells and initiate de novo formation of a primitive 
vessel.  This primitive vessel undergoes angiogenesis, a process that induces 
growth and maturation of the primitive vessel to form a lumenized, branched 
vascular network (6, 7, reviews: 1, 8). The final stages of angiogenesis establish 
blood flow and induce vessel remodeling to further refine the vasculature 6, 7.  
Blood vessels are stabilized by the recruitment of pericytes and vascular smooth 
muscle cells, which encapsulate the developing blood vessels 9.  Together, blood 
vessel formation and stabilization establish a functional network to provide 
nutrients and oxygen throughout the developing organism.  
Blood vessel formation also has important roles in the adult: physiological 
angiogenesis occurs in wound healing or pregnancy, while pathological 
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angiogenesis occurs in conditions such as arthritis, diabetic retinopathy or 
tumorigenesis 10.  Inappropriate blood vessel formation or disruption in vessel 
stability compromises vessel function and contributes to pathology in several 
diseases such as diabetes 1, 11.  Diabetes is characterized by excess blood 
glucose, which induces upregulation of many molecules, including diacylglycerol 
(DAG), VEGF and endothelin-1 (ET1). These molecules impact blood vessel 
formation and function in both developing embryos and adults.   
How angiogenic molecules are differentially regulated in physiological and 
pathological processes is not well understood but currently under investigation.  
Seaman et al. 12 broached this subject by analyzing the vascular transcriptome of 
normal and malignant tissues.  Their analysis revealed that some genes are 
selectively overexpressed in tumor angiogenesis.  Many of these genes encode 
cell surface markers, extracellular matrix (collagen), and placental growth factor 
(PlGF) 12.  PlGF is a VEGF homolog that has been previously implicated in 
pathological angiogenesis 13.  Carmeliet et al. 13 showed that deletion of PlGF 
does not disrupt normal blood vessel formation in the developing embryo.  
However PlGF is required for several pathological properties mediated by VEGF, 
including angiogenesis in ischemia, inflammation and cancer 13.  
We have identified another protein, RasGRP3, that mediates aberrant blood 
vessel formation but is not required for physiological angiogenesis.  Our research 
uses a developmental model of blood vessel formation to simulate pathological 
angiogenesis and address the role of RasGRP3, a Ras activator, in this process.  
We have demonstrated that genetically disrupting Rasgrp3 preserves normal 
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blood vessel formation but inhibit vascular dysmorphogenesis induced by phorbol 
ester, a DAG mimic 14.  Based on these results and data indicating that 
angiogenic vessels express Rasgrp3 in a VEGF-regulated manner 14, we 
hypothesize that RasGRP3 plays a role in pathological processes.  To this end, 
we address the role of RasGRP3 in pathology induced by excess DAG in 
diabetic conditions and test the requirement for RasGRP3 in VEGF or ET1 
signaling in endothelial cells. 
Below, I will briefly discuss VEGF and ET1 signaling pathways and their 
purported roles in vascular pathology.  
 
B.  Vascular Endothelial Growth Factor-A signaling pathways.  Work by 
several groups was seminal to the discovery of a potent angiogenic factor that 
was diffusible and specifically acted on endothelial cells to promote blood vessel 
growth or changes in vessel permeability (review: 15).  Senger et al. 16 first 
demonstrated that conditioned media from tumor cells contained a tumor 
vascular permeability factor (VPF) that increased vascular leakage.  Later work 
showed that this molecule was identical to a diffusible mitogen named vascular 
endothelial growth factor (VEGF) by Ferrara and Henzel 17 (review: 15).  Their 
research has spurred many years of investigation into the role of VEGF in 
physiological and pathological blood vessel formation and function (review: 15). 
The VEGF family is comprised of several family members: VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, and PlGF.  All members regulate growth, migration, survival 
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and permeability to promote blood vessel formation, although VEGF-C and 
VEGF-D are specifically involved in lymphangiogenesis (18, review: 19).  VEGF-A 
(referred to as VEGF) has been well characterized as a critical molecule is 
required for blood vessel formation and deletion of VEGF or its receptors causes 
dramatic vascular defects that result in embryonic lethality 20-22. 
VEGF receptors 1 and 2 (VEGFR-1, VEGFR-2) are common VEGF receptors 
in endothelial cells that mediate vascular patterning.  VEGFR-1 is secreted into 
the extracellular matrix or maintained in a membrane-bound form to regulate 
vessel patterning by acting as a ‘decoy’ receptor to sequester VEGF from 
VEGFR-2 23-28.  Deletion of Vegfr-1 acts as a Vegf gain-of-function perturbation, 
which induces vascular overgrowth and compromises the survival of the 
developing embryo 23.   VEGFR-2 activity is essential for normal angiogenesis 
and regulates endothelial cell proliferation (via ERK signaling), migration (via p38 
MAPK signaling), and survival (via AKT signaling) (Figure 1.1) (review: 29).  
Deletion of Vegfr-2 causes embryonic lethality by perturbing blood island 
formation and subsequent blood vessel formation 29-34. A similar phenotype 
occurs when one or both Vegf alleles are deleted 29-34.  These results indicate 
that there are critical requirements for VEGF concentration or presentation in 
endothelial cells.  While VEGF is required at physiological levels for proper 
angiogenesis, excess VEGF contributes to vascular pathology by inducing 
aberrant angiogenesis or vessel dysfunction such as increased vessel 
permeability in diabetes 35. 
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Misexpression and misregulation of VEGF induces vessel dysfunction in 
pathologies including cardiovascular disease and proliferative diabetic 
retinopathy (13, 36-41, review: 1).  In diabetes, excess glucose disrupts vessel 
function and creates hypoxic tissues to increase VEGF production.  Elevated 
VEGF induces endothelial cell activation by promoting several pathways, 
including ERK 29, 42.  To initiate ERK signaling, VEGFR-2 induces phospholipase 
C (PLC) activation to generate membrane-bound diacylglycerol (DAG) and 
cytosolic inositol trisphosphate (IP3), which stimulates calcium release from the 
endoplasmic reticulum.  A generic version of this pathway is illustrated in Figure 
1.2.  DAG acts as a second messenger to relay signals from activated receptors 
to intracellular proteins by recruiting protein kinase C (PKC) and non-PKC 
proteins with C1 domains such as RasGRP3, to the plasma membrane for 
activation.   PKC phosphorylates Ras activators such as RasGRP3 to mediate 
Ras GTPase (Ras) activation, which acts through the intermediary proteins Raf 
kinase (Raf) and mitogen-activated protein kinase kinase (MEK) to stimulate 
ERK activation 14, 43, 44.  PKC can also bypass Ras to activate Raf and induce 
ERK activation 45. The role of RasGRP3 in DAG-mediated signals has been 
characterized in B-cells using phorbol ester, a DAG mimic 46-52.  Our work 
extends this investigation to endothelial cells.  We also identify an upstream input 
for the RasGRP3 signaling cascade in endothelial cells that is relevant in vivo.  
Determining when RasGRP3 pathways are active in DAG-PKC signaling 
cascades has been challenging because DAG-PKC signaling cascades are not 
limited to VEGF signaling.  DAG-PKC signaling cascades are also activated by 
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many other growth factor or G-protein-coupled receptors, including those 
downstream of ET1 (53, reviews: 54-57). 
 
 C. Endothelin-1 signaling pathways.  In 1985, Hickey et al. observed that 
conditioned media from bovine aortic endothelial cells displayed vasoactive 
effects on isolated rings of the porcine coronary artery.  They attributed the 
changes in vessel tone to the presence of an endothelium-derived contractile 
factor in the conditioned media 58.  Subsequently, another group purified this 
contractile factor and named it “endothelin” (59, reviews: 60, 61).  There are 3 
different endothelin (ET) isoforms, ET1, ET2, and ET3 (62, reviews: 60, 61, 63).  ET 
is generated through a series of cleavage events.  First, a 212-amino acid 
precursor called pre-proET is cleaved by a furin-like endopeptidase into “big ET”, 
a 38-amino acid protein.  “Big ET” is then cleaved by endothelin-converting 
enzyme (ECE) to form active ET, a 21-amino acid protein (62, reviews: 60, 61, 63).  I 
am interested in ET1 because ET1 is the predominant form produced in 
endothelial cells and the most potent vasoconstrictor in the vasculature (59, 
reviews: 60, 61, 63).  
ET signaling is mediated by two G-protein coupled receptors, type A and type 
B (ETAR, ETBR).  ETAR is predominantly expressed in vascular smooth muscle 
cells and binds ET1 and ET2 with the same affinity but has a much lower affinity 
for ET3 (64, review: 57).  ETBR is primarily expressed in endothelial cells and binds 
all ET isoforms with equal affinity.  Both receptors bind a family of heterotrimeric 
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G proteins to transmit signals intracellularly and promote activation of the Ras 
superfamily of small GTPases 65, 66, which I will discuss later.  Heterotrimeric G 
proteins are comprised of α, β, and γ subunits (67).  Gα subunits consist of 
several subtypes Gα12/13, Gαq/11 (Gαq), Gαi, and Gαs, some of which are 
activated by ET receptors (67, 68, review: 69).  ETAR stimulates the Gα proteins 
Gαs and Gαq, and ETBR induces Gαq and Gαi activation (70, review: 69).  The 
consequences of G protein signaling downstream of ET receptor activation in 
various cell types, physiologically and pathologically, are not well understood 
(review: 69).  However, typical Gαs signaling promotes cyclic AMP pathways, 
which are blocked by Gαi signaling 70.  In endothelial cells, ET1-ETBR signaling 
activates PLC through Gαq and Gβ/Gγ to generate DAG, which promotes Ras 
and ERK activation (Figure 1.2) (71, 72, review: 69).  Gαi signaling also promotes 
RasGTPase activity by stimulating a Ras activator called son-of-sevenless 73.  
Similar to VEGF-VEGFR-2 signaling, misregulation of ET1-ETBR signaling 
can promote neoangiogenesis 41, 74 or endothelial activation by stimulating ERK, 
p38 MAPK, and AKT pathways to mediate changes in endothelial cell 
proliferation, migration and survival (Figure 1.3) 75-77.  ET1 also regulates 
vascular tone by inducing vasodilation in endothelial cells and vasoconstriction in 
vascular smooth muscle cells (Figure 1.3) (78, 79, reviews: 80, 81).  ET1 and VEGF 
display synergistic relationships by exhibiting reciprocal transcriptional 
upregulation 76, 82 and cooperatively promoting angiogenesis 77. However, ET1 
and VEGF have distinct functions in the vasculature:  VEGF has been well 
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documented as a promoter of angiogenesis while ET1 is better characterized as 
a regulator of vascular homeostasis 83. 
In the developing embryo, homozygous deletions of endothelin-converting 
enzyme (ECE), ET1 or ETAR cause craniofacial and cardiac abnormalities, 
contributing to respiratory failure and postnatal death (84, 85, reviews: 4, 60).  
Deletion of ETBR also causes lethal colonic aganglionosis, resulting in juvenile 
death (85-87, reviews: 4, 60).  These phenotypes illustrate roles for ET1 outside the 
vasculature.  Unlike VEGF, lack of ET1 does not prevent physiological 
angiogenesis (79, reviews: 88).  In this way, ET1 is similar to RasGRP3 and PlGF 
as discussed previously (13, 14, reviews: 88).   Although elevated ET1 levels have 
been documented in tumorigenesis (reviews: 88), the role of ET1 in pathological 
angiogenesis is not well understood.  Previous work has shown that ET1 acts 
cooperatively with VEGF to induce angiogenesis in a matrigel plug assay in mice 
77.  ET1 also induces changes in vascular homeostasis by increasing blood 
pressure and kidney dysfunction (89-91, review: 55).  In studies of hypertensive-
diabetic rats, ET1-induced hypertension required Ras GTPase signaling 89-91.  
These data suggest that Ras signaling is important in ET1-mediated vascular 
dysfunction.   
 
D. Ras GTPases. The Ras superfamily of small GTPases has over 20 
members and regulates many cellular processes, such as cell proliferation, 
migration, differentiation and apoptosis (44, 92, reviews: 93-95).  One particular Ras 
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GTPase subfamily is comprised of several members: R-Ras, K-Ras, H-Ras and 
N-Ras.  With the exception of R-Ras, Ras members recognize distinct effector 
proteins to modulate downstream signals, promoting ERK activation and inducing 
proliferation and migration (92, 96-98, reviews: 93-95).   
K-Ras, H-Ras and N-Ras are upregulated in many cancers (99, reviews: 100-
104).  Studies that assess K-Ras and H-Ras in tumor models demonstrate that 
Ras is required to promote VEGF transcription and translation to mediate tumor 
growth and neoangiogenesis (105, 106, review: 104).  Murine embryos lacking H-ras 
and/or N-ras develop normally.  However, genetic deletion of K-ras disrupts 
embryogenesis and causes death between embryonic day 12 and birth 107.  To 
explore the effects of Ras signaling in K-ras-specific compartments, Potenza et 
al. 107 expressed H-ras under the control of the K-ras promoter.  Their elegant 
experiments demonstrate that while H-ras expression rescues embryogenesis, 
adult mice experience dilated cardiomyopathy associated with increased 
hypertension. Transgenic mice expressing constitutively activated H-Ras also 
display hypertension.  Interestingly, recent work by Chamorro-Jorganes et al. 108 
indicates that although H-ras-deficient mice appear normal, they are hypotensive, 
which occurs as a consequence of increased vasodilation or impaired 
vasoconstriction. Collectively, these studies indicate that K-Ras and H-Ras 
pathways mediate angiogenesis and also play important roles in vascular 
homeostasis 89-91, 105, 107, 108. 
Ras activation is mediated by conformational changes between active (GTP-
bound) or inactive (GDP-bound) states. Direct interaction with Ras guanine 
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nucleotide exchange factors (RasGEFs) catalyzes the exchange of GDP for GTP 
to activate Ras.  Active Ras then promotes cell signaling until GTP hydrolysis 
returns Ras to a GDP-bound state, a process that is enhanced by Ras GTPase 
activating proteins (RasGAPs) (109-112, reviews: 94, 113, 114).  Mechanisms that 
regulate Ras activation are of key interest to understanding how Ras signaling 
mediates pathologies, such as aberrant angiogenesis or increased hypertension. 
Several RasGEFs mediate Ras activation including son-of-sevenless (SOS), 
Ras-specific guanine nucleotide-releasing factors (RasGRFs) and Ras-specific 
guanine guanyl-releasing proteins (RasGRPs).  Growth factor receptor signaling 
induces SOS activity via complex formation between SOS, two adaptor proteins 
(Shc and Grb2), and c-Src, a non-receptor family tyrosine kinase (115, reviews: 
114, 116, 117).  RasGRFs are constitutively localized to plasma membranes and 
regulated by phosphorylation and calcium (110, 115, 118, review: 114).  RasGRPs are 
typically regulated by DAG and PKC to mediate Ras activation.  Because our lab 
studies a member of the RasGRP family, RasGRP3, I will discuss this RasGEF 
family further in the next section.   
In addition to these RasGEF families, Ras is also activated by PKC.  PKC can 
stimulate Ras activity through sphingosine kinase or specific RasGRPs, including 
RasGRP3 44, 115, 119.  PKC proteins are divided into several functional classes: 
conventional, novel, and atypical PKCs (47, 120, reviews: 119, 121, 122).  The 
conventional PKCs (PKC-α, PKC-β, PKC-γ) are sensitive to calcium, require 
phospholipids and are activated by DAG.  The novel PKCs (PKC-δ, PKC-ε, PKC-
θ, PKC-η) are calcium-insensitive, but also require phospholipids and DAG for 
   13 
activation.  Finally the atypical PKCs (PKC- ι/λ, PKC-ζ) do not require calcium or 
DAG for activation (47, 120, reviews: 119, 121, 122).  Studies have shown that PKC-δ, 
PKC-θ, and PKC-ε activate RasGRP3 in a Ras-ERK pathway 47, 48, 51, 123.  PKC-β 
has also been shown to activate RasGRP3 in vitro 47, 48, 51, 123. 
 
E. RasGRPs. The RasGRP family consists of 4 members, RasGRP1-4 (14, 50, 
124 reviews: 125-127).  This family activates Ras to promote signaling pathways 
including ERK, AKT, p38 MAPK, and JNK to regulate proliferation, migration, 
survival and differentiation (50-52, 112, 124, 128-133, reviews: 93-95).  
RasGRPs display an expression pattern that indicates an important role for 
these proteins in several systems including the hematopoietic system 14, 50, 52, 131-
135.  RasGRP1 is expressed in brain, kidney, mast cells, T-cells and B-cells, while 
RasGRP4 expression is primarily restricted to mast cells 132, 133.  Loss of 
RasGRP1 causes defects in T-cell development and also autoimmunity, while 
loss of RasGRP4 causes defects in mast cell differentiation and expression (132, 
133, 136 review: 137).  RasGRP2 is expressed in brain, kidney, platelets, and in 
blood vessels 14, 138.  Mice lacking RasGRP2 experience impaired platelet 
aggregation 139.  RasGRP3 is expressed in brain, kidney, endocrine tissue, B-
cells, endothelial cells 14, 47, 140 and also vascular smooth muscle cells (PK 
Randhawa, unpublished data).  Interestingly, RasGRP3 expression in endothelial 
and vascular smooth muscle cells is consistent with cell types that are 
responsive to ET1 signaling.  Loss of RasGRP3 function does not lead to 
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dramatic defects in the vasculature or normal murine development in general 14.  
These mice have a mild B-cell defect, but are otherwise viable and fertile 14, 50.  
Compensatory activity by other RasGEFs, such as RasGRP2, may account for 
the lack of vascular defects. 
RasGRPs are characterized by several domains: EF hands, a C1 domain, 
and a catalytic region, which is comprised of a CDC25 box and a Ras exchange 
motif (REM box). The catalytic region is required for GTP exchange to activate 
Ras GTPases.  These domains in RasGRP3 are illustrated in Figure 1.4.  
RasGRP3 also has a recently identified dynein light-chain binding domain 
(DLC1), which is hypothesized to regulate localization of inactive RasGRP3 141 
(Figure 1.4).  EF hands bind calcium, but their role in RasGRP3 signaling has not 
been elucidated.  The C1 domain is homologous to the C1 domain on PKC and 
is bound by DAG to recruit RasGRP3 to plasma membranes.  Once RasGRP3 is 
localized to the plasma membrane, RasGRP3 is activated by PKC, which 
phosphorylates RasGRP3 at threonine-133 located in the catalytic region 48, 50.  
RasGRP3 activity mediates H-Ras, R-Ras, and Rap1 activation.  Rap1 is another 
GTPase distantly related to Ras that promotes cell adhesion and also modulates 
migration 142-145.  
Until recently, there was relatively little investigation to directly assess the role 
of RasGRP3 in pathology.  Genetic screens have linked elevated RasGRP3 
expression to systemic lupus erythematosus, an autoimmune disease, and 
young-onset hypertension, which suggests a connection to elevated ET1 
signaling 146-148.  Work by Yang et al. 112 identified a role for RasGRP3 in prostate 
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cancer. They demonstrated that RasGRP3 is highly expressed in prostate cancer 
cells and mediates cell proliferation, migration, Ras, ERK, and AKT activation 112.  
They also showed that RasGRP3 is required for these cells to maintain their 
metastatic phenotype 112. Together, these studies suggest that RasGRP3 may be 
instrumental in the progression of several diseases, some of which we 
hypothesize to have vascular specific effects.  Since endothelial cells express 
RasGRP3, I hypothesize that RasGRP3 regulates ET1-mediated changes in Ras 
signaling, proliferation and migration in endothelial cells.  I also identify a role for 
RasGRP3 in ET1-induced vessel dysmorphogenesis using an embryonic stem 
cell model of blood vessel formation. 
Roberts et al. have previously shown that Rasgrp3 is a VEGF-responsive 
gene in endothelial cells and that genetic disruption of Rasgrp3 using a gene trap 
method inhibits phorbol ester-induced vessel dysmorphogenesis 14.  Phorbol 
ester is an unmetabolizable DAG mimic that recruits PKC and RasGRP3 to the 
plasma membrane. These data suggest that RasGRP3 is a primary mediator of 
phorbol ester-induced vessel dysfunction.  Phorbol ester stimulation can be used 
to hypothetically model in vivo events downstream of DAG signaling.  In vivo, 
DAG signaling is upregulated in diseases such as diabetes 149.  Therefore, 
phorbol ester can be utilized as a tool to further investigate RasGRP3 function in 
vitro, especially by establishing a requirement for RasGRP3 in phorbol ester-
mediated events.  In this way, we may understand how RasGRP3 may be 
important pathologically in conditions of excess DAG, such as in diabetes.  
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F.  Overview of Diabetes Mellitus. Diabetes is characterized by three 
criteria: excess blood glucose (hyperglycemia), excess free fatty acid release 
(breakdown products of fat storage), and disrupted insulin signaling (reviews: 150, 
151). The hormone insulin, which is produced by beta cells in the pancreas, 
modulates blood glucose and free fatty acid levels. There are two main types of 
diabetes: type 1 and type 2.  In type 1 diabetes, genetic abnormalities cause the 
autoimmune-mediated destruction of the insulin-producing pancreatic beta cells, 
resulting in overall insulin deficiency in the body 152. Type 2 diabetes is the more 
common form of diabetes and is characterized by insulin resistance, which can 
progress to a decrease in insulin production 152.  A third type, called gestational 
diabetes, is a temporary diabetic condition that afflicts some women during later 
stages of pregnancy 152. Diabetes occurs when there is a lack of insulin 
production and/or when cells develop insensitivity to insulin, which further 
promotes hyperglycemic conditions. 
Impact on the developing embryo.  Poor control of maternal hyperglycemia 
has consequences for the developing embryo (149, 153-158, reviews: 159-162).  
Embryos developing in a hyperglycemic environment are 3-5 times more likely to 
suffer from embryonic defects, including defects in the vasculature, neural tube 
closure, or organ development (157, 163-165, reviews: 159-162). These embryos are 
also prone to cardiac defects (155, review: 162, 166) and body axis patterning 
defects such as caudal regression (167, review: 162).  There is also evidence of 
facial malformations in studies of embryos from diabetic mice 163. In terms of the 
vasculature, patterning is disrupted, indicative of impaired angiogenesis, which 
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correlates to reduced endothelial cell proliferation, reduced VEGF signaling, and 
increased apoptosis 168.  
Diabetes-induced embryopathy is also mediated by DAG-PKC signaling 149.  
DAG is elevated by multiple mechanisms as a consequence of PLC activation 
and also glucose metabolism, which induces the de novo synthesis of DAG from 
dihydroxyacetone phosphate and glycerol-3-phosphate (169, review: 170).  As I 
previously mentioned, DAG-PKC signaling cascades mediate Ras-ERK signaling 
47, 48, 51, 123.  Since PKC also regulates RasGRP3-dependent Ras-ERK signaling 
pathway 47, 48, 51, 123, we hypothesize that RasGRP3 mediates diabetes-induced 
embryopathy.  Our findings demonstrate that RasGRP3 is instrumental in 
mediating diabetes-induced embryopathy in mice.   
Impact on adults.  Diabetes decreases life expectancy in adults by an 
average of 5-10 years, which correlates to a 5.4% increase in mortality rate 171.  
Vascular disease accounts for a large majority of these deaths (review: 172).  
Blood vessels undergo many morphological changes such as vessel regression, 
which creates hypoxic tissues, or angiogenesis, which re-establishes routes for 
nutrient delivery. Vessel dysfunction is characterized by changes in hypertension, 
inflammation or thrombosis (reviews: 150, 151).  Pathogenesis is not limited to 
blood vessels but also occurs in many organs including the heart, nerves, eyes 
and kidney (reviews: 173, 174). 
Because diabetes is a multi-factorial disease, it is challenging to understand 
the biochemical and cellular links between elevated blood glucose levels and 
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endothelial dysfunction.  However, many studies have established that glucose 
metabolism can promote endothelial cell activation by elevating many molecules 
including DAG, PKC, ET1, and VEGF (reviews: 159, 160, 175-176).  Given the current 
evidence, we hypothesize that RasGRP3 plays a role in mediating pathways 
consistent with upregulated DAG, PKC VEGF and ET1 in diabetes.  The work 
presented in this dissertation seeks to elucidate the role of RasGRP3 in 
endothelial cells and to understand how RasGRP3 mediates endothelial 
dysfunction in a way that may be consistent with those associated with diabetic 
complications.  Our research demonstrates how perturbations of RasGRP3 
impact phorbol ester- and ET1-mediated Ras-ERK signaling and ET1-induced 
































Figure 1.1 VEGF-VEGFR2 Signaling Pathways.  Through VEGF-R2, VEGF 
signaling pathways regulate blood vessel formation and function.  VEGF induces 
pathways that mediate proliferation (ERK signaling), migration (p38 MAPK 
signaling), permeability (AKT signaling), and survival (AKT signaling).  VEGF-































































Figure 1.2.  Generic DAG-PKC signaling pathways promote Ras and ERK 
activation. Ligand-receptor engagement induces activation of PLC, which 
cleaves PIP2 to generate cytosolic IP3 and membrane-bound DAG.  DAG binds 
the C1 domain of PKC, or other non-PKC proteins such as RasGRP3.  PKC 
initiates ERK signaling cascades by activating other Ras activators, such as 
RasGRP3, or by directly inducing Raf activity.  Raf activates MEK, which 
phosphorylates ERK.  DAG-PKC signaling cascades promote endothelial cell 
activation and vessel dysfunction by inducing changes in endothelial cell 
behaviors such as proliferation and migration.  In this dissertation, we test VEGF 
and ET1 as two ligands that promote DAG-PKC signaling cascades.  We also 
use phorbol ester (phorbol 12-myristate 13-acetate, PMA) to mimic DAG and 





























































Figure 1.3.  ET1-ETBR Signaling Pathways.  Through ETBR, ET1 signaling 
pathways regulate blood vessel formation and function.  ET1 induces pathways 
that mediate proliferation (ERK signaling), migration (p38 MAPK signaling), and 
survival (AKT signaling).  ET1 signaling also induces vasodilation (NO 
generation) in endothelial cells and vasoconstriction (AKT signaling) in vascular 
smooth muscle cells.  ET1-induced Ras activation also mediates many of these 
processes.  ETBR is coupled to heterotrimeric G proteins, Gαq or Gαi, and Gβ 
and Gγ.  Gαq and Gβ/Gγ subunits activate PLC to generate DAG and mediate 
PKC, Ras, and ERK signals.  Gβ/Gγ subunits stimulate signals to promote AKT 



























































Figure 1.4.  RasGRP3: Structure and Function.  RasGRP3 consists of several 
domains.  Starting from the C-terminus, RasGRP3 contains a DLC1 binding 
domain, the function of which in vivo is not clear but is hypothesized to regulate 
RasGRP3 localization.  The C1 domain regulates RasGRP3 recruitment to the 
plasma membrane when bound by DAG or PMA, a DAG mimic.  DAG/PMA also 
bind the C1 domain of PKC, which phosphorylates RasGRP3 at position 
Threonine 133 (T133) for activation.  The function of the EF calcium binding 
hands in RasGRP3 signaling pathways is not known.  The catalytic region is 
comprised of the Ras-exchanger-motif (REM) and CDC25 domains.  The binding 
of the CDC25 domain to Ras-GDP is stabilized by the REM domain.  As a Ras 
guanyl nucleotide exchange factor, RasGRP3 exchanges GDP for GTP to 
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The Ras activator RasGRP3 mediates diabetes-induced embryonic 
defects and affects endothelial cell migration  
 
This chapter is a manuscript submitted to the journal Circulation Research 
(Randhawa et al., in revision).  My focus is studying the effects of Rasgrp3 loss-
of-function in endothelial cells.  I characterized endothelial cells isolated from 
wildtype and Rasgrp3gt/gt mice (Supplemental Figure 2.6). Dr. Svetlana Rylova 
conducted the experiments using endothelial cells that over-express activated 
RasGRP3 (Figures 2.2, 2.3).  Dr. Rylova and I performed the Ras and ERK 
activation assays to assess the requirement of RasGRP3 in phorbol ester 
signaling (Figure 2.4 A).  I generated the data demonstrating that RasGRP3 is 
required for Ras-ERK activation induced by ET1 and not VEGF (Figures 2.4 B, 
C).  I also showed that RasGRP3 is required for ET1-induced endothelial cell 
proliferation (Figure 2.5). In collaboration with Stephanie Kiser, we generated 
Figures 2.5 and 2.6.  Joanna Fried performed whole embryo culture experiments 
and characterized embryos on the outbred background (Supplemental Figures 
2.1, 2.2, 2.3).  Under my mentorship, Jessica Heinz characterized diabetes-
induced embryopathy in the inbred background using STZ-injected WT or 
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Rasgrp3gt/gt mice and Ins2Akita/+ or Ins2Akita/+;Rasgrp3gt/gt mice (Figure 2.1).  
Former graduate students, Dave Roberts and Will Dunworth, generated 
Supplemental Figures 2.7 and 2.8. 
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A.  Abstract 
Rationale:  Fetuses that develop in diabetic mothers have a higher incidence of 
birth defects that include cardiovascular defects, but the signaling pathways that 
mediate these developmental effects are poorly understood.  It is reasonable to 
hypothesize that diabetic maternal effects are mediated by one or more 
pathways activated downstream of aberrant glucose metabolism, since poorly 
controlled maternal glucose levels correlate with the frequency and severity of 
the defects. 
Objective:  We asked whether RasGRP3, a Ras activator expressed in 
developing blood vessels, mediates diabetes-induced vascular developmental 
defects. 
RasGRP3 is activated by diacylglycerol (DAG), and DAG is over-produced by 
aberrant glucose metabolism in diabetic individuals.  We also investigated the 
effects of over-activation and loss-of-function for RasGRP3 in primary endothelial 
cells and developing vessels.  
Methods and Results:  Analysis of mouse embryos from diabetic mothers 
showed that diabetes-induced developmental defects were dramatically 
attenuated in embryos lacking Rasgrp3 function.  Endothelial cells that 
expressed activated RasGRP3 had elevated Ras-ERK signaling and perturbed 
migration, while endothelial cells lacking Rasgrp3 function had attenuated Ras-
ERK signaling and did not migrate in response to endothelin-1.   
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Developing blood vessels exhibited endothelin-stimulated vessel 
dysmorphogenesis that required Rasgrp3 function. 
Conclusions:  These findings provide the first evidence that RasGRP3 
contributes to developmental defects found in embryos developing in a diabetic 
environment.  The results also elucidate RasGRP3-mediated signaling in 
endothelial cells, and identify endothelin-1 as an upstream input and 
Ras/MEK/ERK as a downstream effector pathway.  RasGRP3 may be a novel 
therapeutic target for the fetal complications of diabetes. 
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B.  Introduction 
Receptor-mediated signaling is required for endothelial cell proliferation and 
migration, processes that are critical to blood vessel formation and function 1.  
Signaling downstream of receptor engagement in endothelial cells leads to the 
activation of several pathways, including PLCγ activation to produce 
diacylglycerol (DAG).  DAG in turn activates downstream targets to affect 
endothelial cell behaviors.  Signals that are up-regulated in diabetes, such as 
VEGF-A and endothelin-1 (ET1), generate DAG.  DAG is also produced by 
aberrant glucose metabolism, and DAG levels are elevated in diabetic animals 
and patients 2, 3.  Diabetic individuals have compromised angiogenesis and blood 
vessel function, and fetuses of diabetic mothers have an increased incidence of 
birth defects, including vascular defects 3, 4.  It is assumed that these vascular 
defects are mediated, at least in part, by elevated DAG levels, since mouse 
embryos recovered from diabetic mothers had elevated DAG levels and 
increased developmental defects 3.   However, it is not fully understood how 
elevated DAG leads to vessel dysfunction. 
The effects of DAG on cell signaling are mimicked by phorbol esters, tumor 
promoters that also affect endothelial proliferation, cellular morphology, 
apoptosis, and barrier function 5-9.  DAG and phorbol esters are potent activators 
of the PKC family of proteins.  Numerous mammalian PKC isoforms fall into 
several sub-families, and DAG/phorbol esters activate PKC signaling by binding 
to C1 domains found in the classic (PKCα, β, γ) and novel (PKCδ, ε, η, θ) sub-
groups of PKCs 10.  Recently several non-PKC protein families were identified 
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that contain C1 domains and respond to DAG and phorbol esters, suggesting 
that some DAG/phorbol ester-mediated responses require these proteins 11.  
RasGRPs are non-PKC DAG/phorbol ester receptors that function as guanine 
nucleotide exchange factors (GEFs) and activate the Ras family of GTPases 12, 
13.  Ras proteins are localized to membranes, and their activation is controlled in 
part by proximity to GEFs, such that recruitment of GEFs to membranes can 
activate Ras.  Both DAG and phorbol esters recruit RasGRPs to membranes via 
the C1 domain.  Active Ras in turn activates several effector pathways such as 
MEK/ERK, p38 MAPK, and JNK.  Ras proteins are activated by phorbol esters in 
cultured endothelial cells 14, and PKCs also contribute to Ras and ERK activation 
in response to phorbol esters in endothelial cells; however, the potential role of 
non-PKC DAG/phorbol ester receptors in this response has not been 
investigated.   
The RasGRP family of non-PKC phorbol ester receptors has 4 family 
members.  The RasGRPs have limited sites of expression in vivo, and genetic 
deletion experiments reveal a non-redundant function for the RasGRPs in 
hematopoietic and endothelial cells.  RasGRP1 transduces signals downstream 
of the T cell receptor for T cell maturation, and both RasGRP1 and RasGRP3 
affect B cell function in complex ways 15-17.  RasGRP2 was recently reported to 
have effects on vascular development in Xenopus 18.  We identified RasGRP3 in 
a murine-based gene-trap screen as a locus expressed in endothelial cells of 
developing vessels and required for mediating the endothelial cell effects of 
DAG/phorbol esters 19.  The expression profile and DAG/phorbol ester 
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interactions suggested that RasGRP3 might mediate the effects of excess DAG 
on developing vessels in diabetes. 
RasGRP3 activates Ras, Rap, and R-ras in vitro and in mouse embryo 
fibroblasts 20.  In addition to requiring DAG/phorbol ester activity for membrane 
localization 21, RasGRP3 is phosphorylated by PKC at Thr133, and this 
phosphorylation is required for RasGRP3 activity in B cells 22, 23.  RasGRP3 also 
binds dynein light chain, a component of a microtubule plus-end directed motor, 
but the significance of this binding in vivo is not clear 24.  We showed that 
RasGRP3 is expressed in angiogenic vessels.  Although a genetic loss-of-
function generated by the gene trap did not affect development, embryonic 
vessels exposed to phorbol ester exhibited dysmorphogenesis that required 
Rasgrp3 function, identifying RasGRP3 as a novel endothelial phorbol ester 
receptor 19.  Here we further characterize the role of RasGRP3-mediated Ras 
signaling in embryos, endothelial cells, and developing vessels.  We find that loss 
of Rasgrp3 function significantly reduces diabetes-induced birth defects in vivo, 
including embryonic vascular defects.  We show that Ras is a target of RasGRP3 
in endothelial cells, and that RasGRP3 is required for ET1-mediated effects on 
vessel morphogenesis.  Our data are consistent with a model in which RasGRP3 
signaling in embryonic endothelial cells transduces signals downstream of DAG 
that affect endothelial cell behaviors and lead to vessel dysmorphogenesis. Thus, 
excess DAG in diabetes likely over-activates RasGRP3, and this contributes to 
the perturbed development of fetuses in diabetic environments. 
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C.  Materials and Methods 
Diabetic mice and embryo analysis  
Female mice (C57Bl/6J purchased from Jackson Laboratories, or Rasgrp3gt/gt  
(a loss-of-function null mutation 19) backcrossed to N8 on the C57Bl/6J 
background) at 6-8 weeks of age were made diabetic following the protocol in 
“Animal Models of Diabetic Complications Consortium”.  Alternatively, Ins2Akita/+ 
mice on the C57Bl6/J background (Jackson Laboratories, #003548) were bred to 
obtain Ins2Akita/+; Rasgrp3gt/gt mice.  Blood glucose was monitored weekly, and 
mice with blood glucose levels over 250 mg/dL were considered diabetic.  Mice 
were mated to genotype-matched males, embryos were harvested at E9.5, fixed, 
and whole mount stained for PECAM as described 25.  Stained embryos were 
imaged and scored for defects as described (Supplemental Methods). 
Whole embryo culture was done on embryos dissected at E7.5 or E8.5, in 
roller bottles as described 26.  Some embryos were treated with 50nM PMA 
(phorbol 12-myristate 13-acetate) and some with 20 mM glucose during the 
culture period.  After 24 hr, embryos were removed and photographed. 
 
Endothelial cells   
HUVEC were purchased from Clonetics, cultured according to manufacturer’s 
protocol, and used between passages 2-8.  Transfections were done using an 
Amaxa nucleofector according to directions.  For staining, cells were fixed, 
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permeabilized, blocked, and incubated with phalloidin-Alexa 555 (Molecular 
Probes).  Migration assays were carried out 48 hr post-transfection as described 
(Supplemental Methods).  Average velocity and distance to origin of cells was 
calculated using trajectory measures as diagrammed in Figure 2.3 J. 
Mouse endothelial cells (wildtype and Rasgrp3gt/gt) were generated and 
expanded as described 27, 28, with minor modifications. Proliferation assays and 
migration assays were as described (Supplemental Methods). 
 
ES cell differentiation and analysis 
Wild type (WT, +/+) and RasGRP3 deficient (Rasgrp3gt/gt) ES cells were 
maintained and differentiated for 8 days as previously described 29. For inhibitor 
studies, day 7 ES cell cultures were pre-treated with the appropriate inhibitor for 
2 hr prior to addition of 100 nM PMA for 24 hr.  For ET1 stimulation, 100 nM ET1 
in fresh medium was added daily between days 5-8.  Antibody staining of ES cell 
cultures was as previously described 25, 29.  Quantitative image analysis of 
PECAM-stained ES cell cultures was performed as previously described 25.  
 
Ras and ERK activation assays 
HUVEC (50-80% transfected by GFP labeling after transfection) or mouse 
endothelial cells were grown to near confluency for 48 hr, serum starved 
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overnight, then processed as described (Appendix A) for Ras-GTP 
immunoprecipitation, or total Ras, pERK, or total ERK Western blots.  
 
D. Results 
Loss of Rasgrp3 protects embryos from diabetes-induced birth defects  
Because RasGRP3 is expressed in developing vessels and somites of mid-
gestation mouse embryos 19, we reasoned that embryos exposed to elevated 
DAG signaling would be susceptible to effects of RasGRP3-mediated signaling in 
vivo.  Thus we examined the effects of elevated DAG/phorbol ester, glucose, and 
the diabetic environment on these stages of mouse development.  We first 
mimicked elevated DAG signaling by incubating mouse embryos harvested at 
E7.5 for 24 hr. in phorbol ester under whole embryo culture conditions 
(Supplemental Figure 2.1).  WT embryos exposed to PMA were severely affected 
(Supplemental Figures 2.1, A-D), with loss of anterior-posterior landmarks, and 
yolk sacs with large cavities.  In contrast, Rasgrp3gt/gt mutant embryos incubated 
under the same conditions were surprisingly intact, and anterior-posterior 
landmarks were evident, along with intact yolk sacs (Supplemental Figures 2.1 E-
H).  We next incubated embryos in 20 mM glucose for 24 hr to mimic the diabetic 
environment (Supplemental Figure 2.2).  Glucose exposure between E8.5 and 
E9.5 led to both vascular and non-vascular defects in WT embryos, while 
Rasgrp3gt/gt mutant embryos were relatively refractory to the teratogenic effects 
of elevated glucose. 
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To more precisely define the effects of a diabetic environment on developing 
embryos, we induced diabetes in female mice, then set up matings and 
examined embryos.  On an outbred background, WT embryos often showed 
quite severe defects, including aberrant somite formation and vessel patterning, 
relative to Rasgrp3gt/gt mutant embryos (Supplemental Figure 2.3).  To make 
more rigorous comparisons, we next examined embryos on the C57Bl6/J inbred 
background.  We induced diabetes chemically via STZ, and we also utilized mice 
carrying the Ins2Akita mutation that induces diabetes genetically.  We monitored 
the average maternal blood glucose at sacrifice via tail bleed, and found the 
following values:  WT STZ, 381 mg/dl; Rasgrp3gt/gt STZ, 448 mg/dl; Ins2Akita; 
Rasgrp3gt/gt 387 mg/dl).  Embryos were harvested from diabetic mothers at E9.5, 
whole-mount stained for PECAM-1 to visualize vessel development and 
patterning, and the severity of defects in head plexus vessels, intersomitic 
vessels, and trunk/somite scored as described in the Methods (Figure 2.1). WT 
embryos from diabetic mothers induced either chemically or genetically had a 
significantly elevated developmental severity index compared to controls (Figures 
2.1 A-B, E, O; Supplemental Figure 2.4).  Closer examination of the somite 
region showed defects in somites and in the pattern of intersomitic vessels 
(Figures 2.1 G-J), and similar defects were seen in the vascular plexus of the 
head (Figures 2.1 K-N).  In contrast, embryos similarly developing in diabetic 
mothers but genetically deficient for Rasgrp3 appeared relatively unaffected, and 
their developmental severity index was significantly lower than WT counterparts, 
and close to control levels (Figures 2.1, C-N, O; Supplemental Figure 2.4).  
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Analysis of yolk sacs from these embryos showed a low level of vascular defects 
that did not significantly correlate with genotype, diabetic condition, or the 
severity of the corresponding embryo (Supplemental Figure 2.5 and data not 
shown). Thus loss of Rasgrp3 function has a protective effect on diabetes-
induced developmental defects, including vascular defects, suggesting that DAG-
mediated activation of RasGRP3 mediates diabetes-induced birth defects. 
 
Ras is a target of RasGRP3 in endothelial cells 
To explore how RasGRP3 signaling contributes to diabetes-induced 
developmental defects, we first analyzed signaling in HUVEC that up-regulated 
RasGRP3 activity, because the developmental defects are predicted to result 
from over-activation of RasGRP3 by DAG (Figure 2.2).  Wild-type RasGRP3 
linked to a GFP reporter, and constructs in which a K-Ras CAAX or H-Ras CAAX 
sequence was linked to the protein, were transiently expressed in HUVEC 
(Figure 2.2 A).  The CAAX sequences localize RasGRP3 to membranes 20, which 
mimics DAG-promoted activation to place the activator in physical proximity to 
Ras.  Thus these constructs are predicted to be “constitutively active” in terms of 
their action on Ras and provide gain-of-function activity independent of any over-
expression effects.  Over-expression of WT RasGRP3 did not significantly 
increase Ras activation over baseline, but both of the CAAX tagged RasGRP3 
proteins stimulated significant Ras activation (Figures 2.2 B, C).  ERK activation 
is downstream of Ras activation, and in HUVEC both CAAX-tagged RasGRP3 
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proteins also significantly induced ERK activation (Figures 2.2 B, C).  These data 
indicate that Ras is a target of RasGRP3 in endothelial cells.  
To examine the cellular responses of endothelial cells to RasGRP3-mediated 
signaling, we examined the effects of RasGRP3 over-activation on the 
cytoskeleton, since in other cell types Ras activation affects the cytoskeleton 30, 
31.  HUVEC expressing the constructs described above were stained for 
microtubules (α-tubulin, data not shown) and actin (phalloidin) (Figures 2.3 A-H).  
The microtubule staining pattern was not affected by over-expression of 
RasGRP3 (data not shown); however, the actin cytoskeleton was dramatically 
altered in endothelial cells over-expressing membrane-localized RasGRP3 
(Figures 2.3 E-H).  RasGRP3-CAAX expressing cells appeared larger and flatter, 
and they had very few actin stress fibers.  Cortical actin was also diminished in 
endothelial cells over-expressing RasGRP3-CAAX.  Since actin stress fibers are 
implicated in proper migration, we investigated the migratory behavior of 
endothelial cells over-expressing RasGRP3 (Figures 2.3 I-L).  Endothelial cells 
over-expressing RasGRP3 were identified by GFP expression, and all cells were 
labeled with cell-tracker (Figure 2.3 I).  Cells were imaged, and the average 
velocity and distance migrated from origin was calculated as described in 
methods (Figure 2.3 J).  None of the RasGRP3 proteins affected the overall 
velocity of the cells, but the CAAX-tagged RasGRP3 proteins both significantly 
inhibited the distance migrated from the origin (Figures 2.3 K-L).  These results 
show that endothelial cells that over-express membrane-localized (and thus 
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activated) RasGRP3 have a perturbed actin cytoskeleton, and an attenuated 
ability to migrate in a forward direction. 
To investigate the effects of loss-of-function for Rasgrp3 on signaling 
pathway(s), endothelial cells were isolated and immortalized from WT and 
Rasgrp3gt/gt mice.  The cells were expanded clonally, and the endothelial identity 
of the cells verified by expression of endothelial markers.  The cell lines were 
greater than 95% positive for PECAM-1, VE-cadherin, and ICAM-2 
(Supplemental Figures 2.6 A-D and data not shown). RT-PCR analysis showed 
loss of RasGRP3 expression in Rasgrp3gt/gt endothelial cells, and growth curves 
showed that WT and Rasgrp3gt/gt endothelial cell grew at similar rates 
(Supplemental Figures 2.6 E-F). 
We asked whether RasGRP3 was necessary for Ras and ERK activation 
downstream of DAG/phorbol ester stimulation.  WT and Rasgrp3gt/gt endothelial 
cells incubated with PMA were evaluated for changes in the levels of Ras and 
ERK activation. WT endothelial cells stimulated with PMA had elevated levels of 
active Ras and active ERK.  In contrast, Rasgrp3gt/gt endothelial cells stimulated 
with PMA showed no detectable Ras activation, and ERK activation was 
attenuated (Figure 2.4 A). These results reveal a requirement for RasGRP3 in 
Ras/ERK signaling downstream of DAG/phorbol ester stimulation in endothelial 
cells. 
We next examined the signaling requirements downstream of RasGRP3 
activation in endothelial cells of developing vessels, utilizing a mouse embryonic 
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stem (ES) cell differentiation model that supports the formation of primitive blood 
vessels in vitro via a programmed differentiation 29, 32, 33.  We previously showed 
that ES cell-derived blood vessels respond to phorbol ester stimulation with a 
dramatic vessel dysmorphogenesis that is dependent on Rasgrp3 function 19 
(Supplemental Figures 2.7 A-D).  We therefore asked whether signaling 
downstream of activated RasGRP3 in developing vessels utilized the Ras 
effector pathways MEK/ERK, p38 MAPK or JNK.  The vessel dysmorphogenesis 
seen upon PMA stimulation was significantly attenuated in the presence of the 
MEK inhibitor U0126 (Supplemental Figures 2.7 E-F, I).  In contrast, the p38 
MAP kinase inhibitor SB203580 had no effect on PMA-induced vessel 
dysmorphogenesis (Supplemental Figures 2.7 G-H, I), and the JNK inhibitor 
SP600125 showed a similar lack of effect (data not shown).  Thus RasGRP3-
dependent DAG/phorbol ester signaling in developing vessels requires MEK but 
not p38 MAPK or JNK downstream of Ras GTPases.  
Activation of RasGRP3 in B cells requires, in addition to membrane 
localization, phosphorylation by PKC.  To test PKC function in endothelial cells, 
we exposed ES-derived vessels to PKC inhibitors concomitant with exposure to 
phorbol ester (Supplemental Figure 2.8).  A general inhibitor of most PKC 
isoforms, BIM (bisindolymaleimide), targets the kinase activity of PKC and not C1 
domain interactions; thus BIM inhibits PKC activation without affecting C1-
domain mediated RasGRP3 activation.  BIM completely blocked phorbol ester 
induced vessel dysmorphogenesis (Supplemental Figures 2.8 C-D, I).  Likewise, 
an inhibitor of the conventional PKC isoforms α and β, Gö6976, completely 
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blocked PMA-induced vessel dysmporphogenesis (Supplemental Figures 2.8 E-
F, I).  A third PKC inhibitor, rottlerin, predominantly affects PKCδ, and it partially 
blocked PMA-induced vessel dysmorphogenesis (Supplemental Figures 2.8 G-H, 
I).  These results show a requirement for PKC activity in phorbol ester-induced 
vessel dysmorphogenesis, and suggest that endothelial RasGRP3 requires 
activation by PKC phosphorylation. 
 
RasGRP3 is required for ET1-mediated Ras and ERK signaling in 
endothelial cells  
Although phorbol ester mimics endogenous DAG production and signaling 
downstream of physiological inputs, it does not identify the physiological signal(s) 
that normally activate RasGRP3-dependent signaling in endothelial cells. To 
identify physiologically relevant signals upstream of RasGRP3 in endothelial 
cells, we investigated signaling mediated by VEGF-A and ET1, two angiogenic 
factors that utilize DAG-Ras-ERK downstream signaling.  WT and Rasgrp3gt/gt 
endothelial cells were stimulated with VEGF or ET1, and levels of active Ras and 
ERK analyzed (Figures 2.4 B-C).  As predicted, WT endothelial cells had 
increased levels of active Ras and ERK upon treatment with either VEGF or ET1.  
In contrast, while Rasgrp3gt/gt endothelial cells had elevated levels of active Ras 
and ERK with VEGF treatment, they showed no increase in active Ras and 
attenuated active ERK with ET1 stimulation. Thus, RasGRP3 is required for Ras 
and ERK activation downstream of ET1 stimulation in endothelial cells. These 
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results identify ET1 as a physiological signal for RasGRP3-mediated signaling in 
endothelial cells. 
 
RasGRP3 is required for ET1-induced stimulation of endothelial cell 
proliferation and migration 
Activation of Ras-ERK signaling by ET1 stimulates endothelial cell 
proliferation and migration 34.  To determine whether ET1-induced endothelial cell 
proliferation and migration were RasGRP3-dependent, WT and Rasgrp3gt/gt 
endothelial cells were treated with ET1 and evaluated.  WT endothelial cells 
exhibited over a 2-fold increase in mitotic index over baseline with ET1 treatment, 
while Rasgrp3gt/gt endothelial cells did not exhibit a significant change in their 
mitotic index with ET1 treatment (Figures 2.5 A-E).  In a Boyden chamber 
migration assay, VEGF induced migration of both WT and Rasgrp3gt/gt endothelial 
cells significantly and to a similar degree.  However, ET1 only stimulated 
migration of WT endothelial cells, and did not significantly induce migration of 
Rasgrp3gt/gt endothelial cells (Figure 2.5 F).  These results indicate that ET1-
induced proliferation and migration require Rasgrp3 function, whereas VEGF-
induced migration occurs independent of RasGRP3.  
 
RasGRP3 mediates vessel dysmorphogenesis induced by ET1 
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Since both ET1-induced endothelial cell proliferation and migration are 
RasGRP3-dependent, we asked whether ES cell-derived blood vessels had 
RasGRP3-dependent dysmorphogenesis induced by ET1 (Figure 2.6).  ET1 
treatment of WT vessels led to loss of the fine vascular network and significantly 
increased vascular area (Figures 2.6 A-B, E).  This response was Rasgrp3-
dependent, as Rasgrp3gt/gt vessels retained the fine vascular network and did not 
exhibit increased vascular area under with ET1 treatment (Figures 2.6 C-D, E).  
Thus, developing vessels exhibit vessel dysmorphogenesis in response to ET1, 
and that response requires RasGRP3.  Taken together, these data suggest that 
RasGRP3 is required for ET1-induced endothelial cell angiogenic responses. 
 
E.  Discussion 
RasGRP3 is an activator of Ras family GTPases that is expressed in 
angiogenic vessels and required for the DAG/phorbol ester-mediated responses 
of these vessels.  Here we posit that RasGRP3 is over-activated in embryos 
developing in a diabetic environment and susceptible to birth defects, and we 
show that loss of RasGRP3 significantly attenuates the detrimental effects of a 
diabetic environment on embryonic vascular development.  We also define the 
molecular and cellular processes perturbed by DAG/phorbol ester-induced 
activation of RasGRP3 activation in endothelial cells of developing vessels.  We 
define ET1 as an upstream input and Ras as a target of RasGRP3 in endothelial 
cells, and we show that manipulation of RasGRP3 perturbs endothelial migration.  
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These data lead to a model of RasGRP3-mediated signaling in endothelial cells 
that includes a molecular mechanism, cellular phenotype, and effects on the 
developing embryo in a diabetic environment (Figure 2.7).  
We activated RasGRP3 in developing vessels using phorbol ester as a DAG 
mimic, and RasGRP3-dependent vessel dysmorphogenesis required MEK/ERK 
signaling.  Our data indicates that Ras is a primary target of RasGRP3 in 
endothelial cells, since over-expression of RasGRP3 linked to either K-Ras 
CAAX or H-Ras CAAX domains significantly activated both Ras and ERK, while 
loss-of-function analysis showed that RasGRP3 was required for ET1- or 
DAG/phorbol ester-mediated Ras and MEK/ERK activation.  Our data do not rule 
out that RasGRP3 activates other Ras GTPases in endothelial cells, but they 
suggest that signaling through Ras to MEK/ERK is critical for the vascular 
response to DAG.  RasGRP3 is normally activated by both localization to 
membranes via DAG binding to its C1 domain and by PKC phosphorylation 12.  
Over-expression of RasGRP3 alone was not sufficient to activate endothelial 
Ras, but over-expression of membrane localized forms was sufficient for 
activation, suggesting that endogenous PKC levels are not rate-limiting for 
RasGRP3 activation in endothelial cells.  Our studies also reveal a requirement 
for classical/novel PKC isoform activity in the response of developing vessels to 
DAG/phorbol esters.  While it is possible that the PKC requirement is 
downstream of the genetic requirement for RasGRP3, we favor the hypothesis 
that PKC phosphorylation of RasGRP3 is required for its activity in endothelial 
cells, as has been shown in B cells 22, 23.  
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Elevated RasGRP3 activity affects specific cellular responses of endothelial 
cells.  Endothelial cells that over-express activated RasGRP3 are flattened 
relative to controls, a phenotype also observed in neural cells expressing 
activated RasGRP3 20.  Consistent with this phenotype, the actin cytoskeleton is 
perturbed in these cells, with loss of stress fibers and reduction of the cortical 
actin ring.  The perturbation of the actin cytoskeleton in endothelial cells that 
over-express RasGRP3 is similar to actin perturbations seen in tumor cells that 
express activated Ras 35-37.  In general, Ras activation reduces actin stress fiber 
formation, primarily through effects on RhoA activity, but also via MEK signaling 
to ERK1/2 and ERK5 30, 31, 38.  Actin stress fibers link to focal adhesions on the 
ventral side of cells, and this linkage promotes acto-myosin contractility 39, 40.  In 
terms of migration, stress fibers are thought to act as rudders that keep cells 
migrating directionally 41, 42.  Consistent with this idea, we find that endothelial 
cells over-expressing activated RasGRP3 have normal velocity but significantly 
reduced migration relative to the origin over time.  This finding suggests that the 
cells can move, but their ability to link one movement to the next in a coordinated 
fashion is impaired.  Thus, over-expression of activated RasGRP3 mimics Ras 
over-activation and prevents orderly forward migration of endothelial cells. 
Complementary loss-of-function analysis showed that Rasgrp3 function is 
required for DAG/phorbol ester mediated Ras activation, as is predicted to occur 
in diabetic environments with elevated DAG levels.  Interestingly, RasGRP3 is 
involved in Ras/ERK signaling downstream of ET1 in endothelial cells.  ET1 is 
elevated in diabetic milieus 43 and leads to DAG production, so perhaps two 
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sources of DAG – DAG produced via elevated glucose and DAG produced via 
elevated ET1 signaling, contribute to RasGRP3-mediated vascular pathologies in 
diabetic animals.  In contrast, a second signal that is elevated in diabetic 
environments, VEGF-A, does not appear to require RasGRP3 for Ras-mediated 
signaling, although RasGRP3 expression is up-regulated by VEGF-A 19.  Several 
studies reported that ET1 angiogenic effects required VEGF-A 44, 45.  In light of 
our work, it is possible that this VEGF-A requirement reflects a need for VEGF-A-
stimulated RasGRP3 expression.  Thus, the requirement for RasGRP3 in ET1-
mediated signaling may link the activities of the two pathways in diabetes.  
Because diabetes is accompanied by elevated DAG levels and leads to 
developmental defects, including vascular defects, we hypothesized that in a 
diabetic fetal environment elevated maternal glucose crosses the placenta, 
where it is metabolized to DAG.  The excess DAG ectopically activates 
embryonic RasGRP3, and downstream activation of Ras signaling contributes to 
the increased incidence of developmental problems.  This hypothesis predicts 
that embryos lacking Rasgrp3 are less susceptible to diabetes-induced birth 
defects, and in fact embryos lacking Rasgrp3 were significantly protected from 
developmental defects produced in a diabetic fetal environment.  This was true 
whether the mothers were diabetic from STZ destruction of pancreatic β cells or 
via the Ins2Akita mutation, which inactivates the insulin II gene and thus leads to 
diabetes 46.  The embryonic defects we documented were similar to the defects 
reported by others 3, 4. Interestingly, embryos that lacked Rasgp3 function and 
developed in diabetic mothers had significantly fewer defects in developing 
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somites and developing vessels, two embryonic organs that express RasGRP3 
19.  The vascular defects seen in WT embryos from diabetic mothers were 
consistent with the endothelial migration defects observed in primary endothelial 
cells, since the intersomitic vessels were sometimes blunted, with expanded 
migratory fronts.  Interestingly, while yolk sac vessels showed some pattern 
defects, these did not significantly correlate with embryo genotype, diabetic 
environment, or overall embryo defects, in contrast to another group who 
described significant diabetes-induced yolk sac vasculopathy 4, 47.  This indicates 
that the observed diabetes-induced embryonic defects were not secondary to 
yolk sac defects that compromised overall embryonic health.   
Was the protection afforded by loss of RasGRP3 from the maternal 
compartment, the embryonic compartment, or both?  Several lines of evidence 
support a critical role for embryonic Rasgrp3 function in mediating the effects of 
diabetes.  First, another study showed that DAG levels and activated PKC are 
elevated in embryos from diabetic mothers 3, indicating that upstream 
requirements for RasGRP3 activation are in place in the embryo.  In our work, 
mothers lacking RasGRP3 became diabetic, and their average blood glucose at 
sacrifice was higher than WT controls. Whole embryo culture using medium 
supplemented with PMA showed that embryos lacking Rasgrp3 were significantly 
protected from the severe PMA-induced perturbations seen in WT embryos.  
Finally, embryos exposed to elevated glucose had increased defects that were 
RasGRP3-dependent, showing that the RasGRP3 status of the embryo is critical 
to its response to maternal glucose. Taken together, these findings indicate that 
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lack of Rasgrp3 function in the embryo is critical for protection from 
developmental defects, and that potential maternal effects of Rasgrp3 loss do not 
impact the elevated glucose levels that lead to elevated DAG and diabetes.   
The finding that RasGRP3 mediates the effects of a diabetic environment on 
embryonic development, including vascular development, suggests that 
RasGRP3 may be a new and useful therapeutic target for prevention of diabetes-
associated birth defects.  The lack of embryonic defects with Rasgrp3 loss-of-
function under normal conditions (this study and 19) indicates that blockade of 
RasGRP3 is not detrimental to overall development.  The focus of this study was 
analysis of gain- and loss-of-function for RasGRP3 in developing vessels and 
endothelial cells, and we show that RasGRP3-mediated signaling uses Ras/ERK 
as a target and mediates ET1 effects on angiogenesis.  It will be interesting to 

















Figure 2.1.  Loss of RasGRP3 attenuates diabetes-induced developmental 
defects.  WT (A, B, G, K) and Rasgrp3gt/gt (C, D, H, L) E9.5 embryos were 
isolated from mothers made diabetic with STZ (B, D, G, H, K, L), or isolated from 
Ins2Akita (E, I, M) or Ins2Akita; Rasgrp3gt/gt (F,J, N) diabetic mothers and stained for 
PECAM.  (A) WT embryos from non-diabetic WT mothers have few defects, 
while (B) WT embryos from diabetic mothers have defects in the somitic 
vasculature (arrow), head plexus (arrow), and somites; (C) Rasgrp3gt/gt embryos 
from Rasgrp3gt/gt non-diabetic mothers have few defects, and (D) Rasgrp3gt/gt 
embryos from Rasgrp3gt/gt diabetic mothers are also relatively normal.  (E) 
Embryos from Ins2Akita; Rasgrp3+/+ mothers have somitic vessel and head plexus 
defects (arrows), whereas (F) embryos from Ins2Akita; Rasgrp3gt/gt mothers have 
few defects.  (G-J) Close-up of somitic regions of embryos of indicated 
genotypes; (K-N) close-up of head plexus regions of embryos of indicated 
genotypes.  Arrows point to defects in vascular pattern.  (O) The developmental 
severity index was calculated on groups of embryos as described in Methods.  
Mother’s genotype and diabetic status: Lane 1, WT non-diabetic (n = 46); Lane 2, 
WT STZ diabetic (n = 51); Lane 3, Rasgrp3gt/gt non-diabetic (n = 25); Lane 4, 
Rasgrp3gt/gt STZ diabetic (n = 27); Lane 5, Ins2Akita; Rasgrp3+/+ diabetic (n = 17); 
Lane 6, Ins2Akita; Rasgrp3gt/gt diabetic (n = 19).  **, p≤0.001 for WT vs. WT-STZ 
diabetic; ***, p≤0.00001 for WT vs. Ins2Akita; ##, p≤0.0001 for Ins2Akita; Rasgrp3+/+ 
vs. Ins2Akita; Rasgrp3gt/gt. 
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Figure 2.2.  Over-expression of activated RasGRP3 activates Ras and ERK 
in endothelial cells.  (A) HUVEC were transiently transfected with the constructs 
shown. (B) IB for GFP linked to RasGRP3 constructs (top panel) shows relative 
expression of the introduced genes; Ras-GTP panel is a Ras blot of Ras-RBD 
(Raf Binding Domain) immunoprecipitation to show activated Ras; Ras panel is 
10% loading of input to show total Ras; pERK panel is blot hybridized with p-ERK 
(activated); ERK is total ERK blot.  Lane 1, HUVEC transfected with GFP control; 
Lane 2, HUVEC transfected with GFP-RasGRP3; Lane 3; HUVEC transfected 
with GFP-RasGRP3-KCAAX; Lane 4; HUVEC transfected with GFP-RasGRP3-
HCAAX. (C) Relative increase in reactivity for active Ras/total Ras (top panel) or 
active ERK/total ERK (bottom panel) relative to GFP control.  *, p≤0.01; **, 
p≤0.002; ***, p≤0.0001, relative to the relevant control. 
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Figure 2.3.  Over-expression of active RasGRP3 perturbs the actin 
cytoskeleton and migration of endothelial cells.  (A-H), HUVEC transfected 
with the indicated constructs were incubated for 48 hr, then fixed and imaged for 
GFP (green) (A-D) or stained with phalloidin (red) (B-H).  (A-B) control GFP-
CAAX; (C-D) GFP-RasGRP3; (E-F) GFP-RasGRP3-KCAAX; (G-H) GFP-
RasGRP3-HCAAX.  Astericks in panels E-H indicate transfected cells with 
perturbed phalloidin staining.  (I-J), HUVEC were labeled with cell-tracker and 
live imaged.  (I) HUVEC expressing GFP-RasGRP3 (green) and labeled with 
celltracker (red); (J) diagram showing how the average velocity (V) and distance 
from origin (D) were calculated from cell trajectories; (K) average velocity; (L) 































Figure 2.4.  RasGRP3 is required for Ras-ERK activation downstream of 
phorbol ester and ET1 but not VEGF-A.  (A) WT and Rasgrp3gt/gt endothelial 
cells were treated with PMA and processed for Ras and ERK activation.  
Compared to WT endothelial cells, Rasgrp3gt/gt endothelial cells did not show 
increased activated Ras (Ras-GTP) and had an attenuated activation of pERK. 
(B) WT and Rasgrp3gt/gt endothelial cells were treated with ET1 or VEGF-A and 
processed for Ras activation. WT endothelial cells had increased levels of 
activated Ras (Ras-GTP) in response to both VEGF and ET1, whereas 
Rasgrp3gt/gt endothelial cells had increased activated Ras (Ras-GTP) in response 
to VEGF-A but an attenuated response to ET1. (C) WT and Rasgrp3gt/gt 
endothelial cells were stimulated with ET1 or VEGF-A and processed for ERK 
activation. WT endothelial cells had increased levels of pERK in response to both 
VEGF and ET1, whereas Rasgrp3gt/gt endothelial cells had increased pERK in 
response to VEGF-A but not in response to ET1. Experiments are representative 































Figure 2.5.  RasGRP3 mediates ET1-induced endothelial cell proliferation 
and migration.  Control (A, C) or ET1-treated (B, D) WT (A, B) or Rasgrp3gt/gt  
(C, D) endothelial cells were stained for PECAM (green) and PH3 (red). (E) 
Representative areas were imaged and mitotic cells counted.  The relative mitotic 
index was significantly increased in WT endothelial cells treated with ET1, but 
was not significantly increased in Rasgrp3gt/gt endothelial cells treated with ET1.  
**, p ≤  0.001 relative to WT untreated; ###, p ≤ 0.001 relative to ET1-treated WT 
endothelial cells.  (F) Transwell migration assays.  WT endothelial cells had 
significantly increased migration towards both ET1 and VEGF-A compared to 
control, whereas Rasgrp3gt/gt endothelial cells had significantly increased 
migration towards VEGF-A but not towards ET1.  *, p ≤ 0.01 relative to untreated; 
















Figure 2.6.  RasGRP3 mediates ET1-induced vessel dysmorphogenesis.  ES 
cell cultures that were WT (A, B) or Rasgrp3gt/gt (C, D) were untreated (A, C) or 
treated with ET1 (B, D), then fixed and stained for PECAM (green) on day 8. (E) 
Representative images were quantified for vascular area.  WT vessels treated 
with ET1 had significantly increased vascular area, whereas ET-1 treated 
































Figure 2.7.  Model of activated RasGRP3 signaling and function in 
endothelial cells.  In this model, maternal diabetic conditions induce elevated 
DAG production in embryos via aberrant glucose metabolism and via ET1 
signaling; endothelial RasGRP3 is over-activated by DAG and PKC 
phosphorylation to activate Ras (Ras-GTP).  Ras signaling through MEK/ERK 



















































Supplemental Figure 2.1.  Loss of Rasgrp3 protects from PMA-induced 
developmental perturbations.   Mouse embryos that were WT (A-D) or mutant 
for Rasgrp3 (E-H) were dissected at E7.5 with yolk sac intact, and incubated for 
24 hr in the presence of 50 nM PMA.  WT embryos uniformly exhibited severe 
defects of the yolk sac and embryo proper, while Rasgrp3gt/gt embryos were 
relatively protected from PMA effects, with discernable anterior (a) and posterior 












































































Supplemental Figure 2.2.  Loss of Rasgrp3 protects from diabetes-induced 
defects. WT (A,B) or Rasgrp3gt/gt (C, D) embryos were dissected from diabetic 
mothers at E8.5 and cultured for 24 hr in control media (A, C) or media with 20 










































































Supplemental Figure 2.3.  Loss of Rasgrp3 protects from diabetes-induced 
defects.  WT (A,B) or Rasgrp3gt/gt (C, D) embryos were dissected from diabetic 
mothers at E9.5 and stained in whole mount for PECAM-1.  (A, B)  arrows point 
to severe defects seen in two different WT embryos; (C, D) two different 



























































































Supplemental Figure 2.4.  Distribution of Embryo Severity Index values 
relative to genotype/condition.  For each group, embryos were scored on a 
scale from 0 (no defects) to 3 (severe defects) as described.  The proportion in 
each category is indicated.  WT, mothers were normo-glycemic; STZ, mothers 





































































Supplemental Figure 2.5.  Lack of yolk sac vascular defects associated with 
genotype/condition.  (A-F) Yolk sacs of E9.5 embryos were processed for 
PECAM (green) immunofluorescence.  No significant trends were found that 






















































Supplemental 2.6.  Characterization of WT and Rasgrp3gt/gt endothelial 
cells.  WT (A, C) and Rasgrp3gt/gt (B, D) endothelial cells were isolated as 
described, and stained for PECAM-1 (A, B) or VE-cadherin (C, D).  (E) RT-PCR 
from RNA isolated from: lane 1, WT day 8 ES cell cultures; lane 2, Rasgrp3gt/gt 
day 8 ES cell cultures; lane 3, WT endothelial cells; and lane 4, Rasgrp3gt/gt 
endothelial cells.  Appropriate primers amplified a RasGRP3 band in WT 
embryos and endothelial cells, while lacZ primers amplified the reporter inserted 
in the gene trap (gt) allele in Rasgrp3gt/gt embryos and endothelial cells.  (F) A 






















































Supplemental Figure 2.7.  RasGRP3-dependent PMA-induced vessel 
dysmorphogenesis is blocked by MEK inhibition.  Day 8 ES cell cultures 
stained for PECAM-1.  (A, C, E, G) control cultures; (B, D, F, H) cultures 
incubated with PMA (100 nM) for 24 hr.  (A,B) WT vessels with no inhibitor; (C,D) 
Rasgrp3gt/gt vessels with no inhibitor; (E,F) Vessels co-incubated with the MEK 
inhibitor U0126; (G,H) Vessels co-incubated with the p38 MAPK inhibitor 
SB203580; (I),Vessel area was quantified. ***, p≤ 0.00001 for -PMA (lane 1) vs. 
+PMA (lane 2); ##, p≤ 0.0001 for +PMA (lane 2) vs. +PMA,+MEK inhibitor (lane 















































Supplemental Figure 2.8.  RasGRP3-dependent PMA-induced vessel 
dysmorphogenesis is blocked by PKC inhibition.  Day 8 ES cell cultures 
stained for PECAM-1.  (A, C, E, G) control cultures; (B, D, F, H) cultures 
incubated with PMA (100 nM) for 24 hr.  (A,B) Vessels with no inhibitor; (C,D) 
Vessels co-incubated with the general PKC inhibitor BIM; (E,F) Vessels co-
incubated with the conventional PKC inhibitor Gö6976; (G, H) Vessels co-
incubated with the PKC inhibitor rottlerin; (I), Vessel area was quantified. ***, p≤ 
0.00001 for -PMA (lane 1) vs. +PMA (lane 2); ##, p≤ 0.001 for +PMA (lane 2) vs. 
+PMA, +BIM inhibitor (lane 4); ###, p≤0.0001 for +PMA (lane 2) vs. +PMA, 
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The delivery of nutrients via the vascular system is tightly regulated by insulin 
signaling.  Disruption of regulatory signals significantly elevates blood glucose 
levels and eventually leads to diabetes.  Metabolism of excess blood glucose 
induces DAG production, and elevated DAG promotes signaling of pathways 
such as VEGF and ET1 in endothelial cells.  Increased levels of DAG, VEGF 
and/or ET1 perturb endothelial behavior and vessel function.  In my work, I 
sought to understand how the Ras activator, RasGRP3, acts to mediate 
endothelial cell behaviors, such as proliferation and migration, and vessel 
dysmorphogenesis.  Because RasGRP3 is activated by DAG, RasGRP3-
dependent regulation of these phenotypes may significantly contribute to 
diabetes-induced embryopathy.  For the first time, I have also identified ET1-
mediated signaling as an upstream input for the RasGRP3 pathway.  However, 
further investigation is required to determine the role of RasGRP3-mediated ET1 
signaling in diabetes-induced pathology. Because diabetes causes vessel 
dysfunction, elucidating the pathophysiological role of RasGRP3 in endothelial 
cells will be informative to develop strategies that will protect the embryo from 
maternal hyperglycemia. 
Diabetes-induced embryonic defects occur most frequently in the heart and 
the central nervous system (1, review: 2-4).  The mechanisms by which maternal 
hyperglycemia causes embryopathy are not well understood.  In Chapter II, work 
by Joanna Fried and Jessica Heinz assessed embryos from wildtype and 
Rasgrp3gtgt diabetic and non-diabetic mice.  Their results demonstrate that loss of 
RasGRP3 confers protection by rescuing diabetes-induced embryopathy, which 
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suggests that RasGRP3 is a strong mediator of this phenotype.  For the purpose 
of this dissertation, we focused on the role of RasGRP3 in mediating vascular 
defects, but intriguingly, loss of RasGRP3 also rescues defects in body-axis 
patterning and neural tube closure. RasGRP3 is expressed in developing 
somites and in glial cells of the adult brain in mice 5, 6.  Over-activation of 
RasGRP3 in developing somites may explain diabetes-induced patterning and 
closure defects.  These results warrant further investigation to determine how 
RasGRP3 mediates diabetes-induced embryopathy, and whether RasGRP3 has 
currently unidentified roles in other systems regulating body segmentation 
(skeletal development) or brain patterning (neural network formation).   
To understand the contribution of RasGRP3 to diabetes-mediated effects, we 
must identify cellular signaling pathways that are mediated by RasGRP3.  Other 
groups have provided evidence that perturbations in RasGRP3 signaling 
significantly impact Ras-ERK signaling 7-13, which we have confirmed in 
endothelial cells using gain- and loss-of function studies.   Work by Dr. Svetlana 
Rylova illustrates that over-expression of activated RasGRP3 alone in endothelial 
cells is sufficient to induce Ras and ERK activation.  Additionally, I have shown 
that loss of RasGRP3 effectively inhibits PMA- or ET1-induced Ras and ERK 
activation.  PMA and ET1 promote activity of both PKC and RasGRP3, which are 
both capable of Ras activation 6-9, 11, 13-15.  Interestingly, our results indicate that 
PMA- and ET1-induced Ras activation is entirely through RasGRP3.  
Surprisingly, RasGRP3 does not affect VEGF-induced Ras and ERK activation, 
suggesting that VEGF either acts independently of RasGRP3 or has redundant 
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mechanisms to compensate for the loss of RasGRP3.  My data imply that 
RasGRP3 is not globally necessary to mediate Ras-ERK signaling but is only 
activated by specific stimuli, such as ET1 signaling.  The results presented here 
confirm that RasGRP3 is required for Ras-ERK signaling promoted by either 
excess DAG, which was simulated with phorbol ester, or by ET1.   
The requirement for RasGRP3 in ET1-induced Ras activation provides some 
perspective on other studies that assess the effects of ET1 signaling in diabetes.  
Other groups have demonstrated that blockade of Ras signaling alleviates ET1-
mediated hypertension in diabetic rats 7-9.  My results suggest that these effects 
are mediated by RasGRP3, and thus RasGRP3 may be a suitable target for Ras 
blockade in ET1-induced hypertension.  ET1-induced hypertension is primarily 
regulated through ETAR, which is highly expressed in vascular smooth muscle 
cells (VSMC) 10-12.  RT-PCR experiments also show that RasGRP3 is expressed 
in VSMC (data not shown).  In Chapter II, we have demonstrated that RasGRP3 
is required for several aspects of ET1 signaling; therefore, it would be interesting 
to determine whether VSMC-derived RasGRP3 also mediates ET1-induced 
hypertension in vivo.  These experiments could be conducted by crossing 
Rasgrp3gt/gt mice with ET1+/- mice, which display elevated blood pressure 11, 12.  
Increased hypertension in ET1+/- mice may be caused by differences in activity 
between nonendothelial- and endothelial-derived ET1, as mice heterozygous for 
an endothelial-specific ET1 deletion display normal blood pressure 11.  If 
RasGRP3 does regulate ET1-induced hypertension, I would expect that 
Rasgrp3gt/gt/ET1+/- offspring to be protected from elevated blood pressure.  To 
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take this a step further, similar studies could be conducted in hypertensive-
diabetic mice.  I would still expect that loss of RasGRP3 would confer protection 
against diabetes-induced hypertension.  These experiments would identify a new 
role for RasGRP3 in ET1-induced hypertension, especially in diabetic 
backgrounds.   
Recent work by Yang et al. 13 determined that RasGRP3 activation increased 
cell proliferation and migration in prostate cancer cells, which we have also 
confirmed in endothelial cells.  For the first time, I show that loss of RasGRP3 
prevents ET1-induced increases in endothelial cell proliferation.  These results 
are consistent with inhibition of Ras-ERK signaling or ET1 signaling in general 
(14-17, review: 18).  Work by Dr. Rylova, Stephanie Kiser and myself illustrates that 
RasGRP3 is required for ET1-mediated migration in endothelial cells.  Dr. Rylova 
shows that over-expression of RasGRP3 causes a reduction in actin stress fibers 
and inhibits directional migration, while other data confirms that RasGRP3 is 
required in ET1-induced migration.  Changes in the cytoskeleton and cell 
adhesion are important to facilitate migration.  The mechanisms by which 
RasGRP3 mediates these processes to promote migration are not clear.  At first 
glance, the data seem counter-intuitive: our results demonstrate that RasGRP3 
positively mediates ET1-induced migration, but over-expression of RasGRP3 
inhibits migration.  I hypothesize that these differences are due to a dosage-
specific requirement for RasGRP3 to mediate such cellular responses.   
Differences in migration can be attributed to specific levels of RasGRP3: 
activated RasGRP3 signaling normally promotes migration, but excessive 
   105 
RasGRP3 signaling inhibits migration.  This is a common phenotype of Rac 
GTPase activation 19, 20.  Rac is known to promote migration by initiating signals 
that down-regulate Rho GTPase to destabilize cell adhesions and stress fibers 20.  
However, over-expression of Rac and complete loss of Rho activation completely 
inhibits migration.  This occurs because cells require some level of structure 
(cytoskeleton) and adhesion to create traction and promote migration.  
Interestingly, we have evidence that a Rac inhibitor partially rescues PMA-
induced vessel dysmorphogenesis, which suggests that Rac may be downstream 
of RasGRP3 (data not shown).  In the future, it would be of interest to determine 
whether RasGRP3-dependent changes on cytoskeleton remodeling and 
migration require Rac.  As discussed in Chapter II, over-expression of RasGRP3 
in endothelial cells inhibits directional migration.  To assess the role of Rac in 
RasGRP3-induced perturbations in migration, I would treat RasGRP3-over-
expressing cells with a Rac inhibitor. I expect that these cells would display a 
dosage-dependent response to the Rac inhibitor.  An optimal concentration 
would promote partial recovery of the actin cytoskeleton and increased migration.  
These results would implicate a role for Rac downstream of RasGRP3 and help 
elucidate whether the loss of directional migration is due to RasGRP3-induced 
Rac over-activation.   
There are many other aspects of RasGRP3 signaling that warrant further 
exploration in order to understand how RasGRP3 functions in vivo.  In addition to 
H-Ras, RasGRP3 can also activate R-Ras and Rap, which add dimension and 
complexity to RasGRP3 signaling 6, 21, 22.  Interactions of multiple signaling 
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cascades could mediate time-sensitive changes and negative feedback 
regulation.  R-Ras is known to activate phosphatidylinositol 3-kinase (PI3K) to 
induce an AKT pathway that inhibits proliferation and directional migration 21, 23.  
Yang et al. 13 have also provided evidence to support a role for RasGRP3 in AKT 
signaling and apoptosis in prostate cancer cells.  This group showed that siRNA-
mediated downregulation of RasGRP3 inhibits Ras, AKT, ERK, proliferation, 
migration and apoptosis 13.  Similar to H-Ras, Rap can also activate ERK to 
promote proliferation, but has varying effects on migration.  Rap is thought to 
inhibit migration by promoting cell adhesion, but other studies have shown that 
Rap also positively mediates migration (24-28, reviews: 29, 30).  Ultimately, 
RasGRP3 potentially acts as a signaling hub to integrate positive and negative 
signals that modulate endothelial cell behaviors.  By identifying other key 
pathways mediated by RasGRP3, we can better understand how RasGRP3 
mediates endothelial dysfunction and vessel dysmorphogenesis. 
ET1 promotes tumor growth and neoangiogenesis (39-44, review: 31).  In 
Chapter II, I show that RasGRP3 is required to mediate ET1-induced vessel 
dysmorphogenesis in a murine embryonic stem cell model.  This 
dysmorphogenesis is representative of misregulated angiogenic behavior, which 
prompts the question: Is there a role for RasGRP3 in ET1-induced angiogenesis 
in vivo? Using wildtype and Rasgrp3gt/gt mice implanted with a matrigel plug, we 
can test the requirement for RasGRP3 in ET1-induced neoangiogenesis.  I 
expect that only angiogenic vessels derived from wildtype and not Rasgrp3gt/gt 
mice would ingress into the ET1-containing matrigel plug.  These data would 
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confirm whether RasGRP3 mediates ET1-induced angiogenesis, further 
contributing to evidence that RasGRP3 is important in pathologic angiogenesis.  
In a model derived from this work, ET1-mediated DAG production requires 
RasGRP3 signaling to promote changes in proliferation or migration, which can 
induce aberrant vessel growth and other diabetes-induced embryonic vascular 
defects (Figure 3.1).  Our model also predicts that RasGRP3 is required for 
phorbol ester pathways to mediate similar changes in endothelial cell behavior or 
vessel morphology (Figure 3.1).  
RasGRP3 has a pathophysiological role that has not been well explored.  
However, there is a growing literature correlating RasGRP3 to various 
pathologies, including young-onset hypertension, lupus erythematosus and 
cancer 13, 32.  Previous work by Roberts et al. demonstrated that RasGRP3 
expression is upregulated in mammary tumors 5, and our current work identifies a 
role for RasGRP3 in diabetes-induced embryopathy.  RasGRP3 is a curious 
protein, because it can mediate pathology even though it is not required for 
normal development.  Interestingly, RasGRP3 is not the only protein in the 
vasculature that behaves this way.  In fact, Zayed et al. 33, identify a similar role 
for calcium and integrin-binding protein-1 (CIB1), a 22 kDa regulatory protein that 
mediates P21/Cdc42/Rac1-activated kinase-1 (PAK1)-induced ERK signaling.  
Similar to RasGRP3, CIB1 is not required for physiological angiogenesis as mice 
lacking CIB1 are viable and appear to develop normally 33, 34.  Zayed et al. 33 
demonstrate that loss of CIB1 attenuates VEGF or FGF induced PAK1 and ERK 
activation in endothelial cells and that CIB1 is required for pathological 
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angiogenesis induced by ischemia or tumorigenesis. Proteins such as CIB1 or 
RasGRP3 are attractive targets to treat aberrant vessel formation, while leaving 
physiological signaling pathways for vessel patterning intact.  Ultimately, 
understanding the cellular outputs of RasGRP3 signaling will help us understand 
the role of RasGRP3 in disease.   
 
A.  Conclusions 
We have identified a novel signaling axis that functions in conditions of 
excess DAG such as diabetes.  Previously, the role of RasGRP3 in diabetes was 
not known, but with this work, we have established that RasGRP3 directly 
mediates diabetes-induced embryopathy, and we have provided a possible 
mechanism for this action.  We show that perturbations in RasGRP3 alone (gain-
of-function or loss-of-function) are sufficient to affect Ras-ERK signaling in 
endothelial cells, and that RasGRP3 is required for PMA- or ET1-induced Ras-
ERK signaling.  For the first time, we have identified ET1 as an upstream input 
for RasGRP3-mediated signaling.  We have established that RasGRP3 is 
required for ET1-induced proliferation and migration in endothelial cells and ET1-
induced aberrant vessel growth in embryonic stem cell-derived vessels (Figure 
3.2).  These novel contributions to the field of vascular biology are important for 
understanding how RasGRP3-mediated signaling affects vessel dysfunction, 



















Figure 3.1. Hypothetical model for RasGRP3-dependent vessel 
dysmorphogenesis induced by PMA or ET1-mediated DAG signaling.  ET1 
signaling promotes DAG generation, which is mimicked by phorbol ester (PMA).  
DAG/phorbol ester-mediated signals activate RasGRP3.  Intact RasGRP3 
signaling can promote endothelial proliferation and migration, which leads to 
vascular dysmorphogenesis and embryopathy in diabetes.  Disruption of 
RasGRP3 signaling pathways inhibits ET1-induced endothelial proliferation and 
migration and vessel morphogenesis or excess DAG signaling in general, which 
confers protection in diabetic backgrounds.  (*) Preliminary experiments suggest 
























































Figure 3.2.  ET1-ETBR signaling promotes a RasGRP3-dependent Ras-ERK 
signaling to promote changes in endothelial cell behavior and vessel 
morphology – a model.  A schematic of proposed ET1 signaling to regulate 
proliferation and migration in endothelial cells.  In this model, ET1 promotes DAG 
generation through Gαq or Gβ/Gγ subunits.  DAG binds the C1 domain of PKC 
and RasGRP3 to recruit them to the plasma membrane.  PKC phosphorylates 
RasGRP3 to promote Ras activation.  RasGRP3 activates Ras, which signals 
through other proteins to activate ERK.  These signals promote changes in 
endothelial cell behavior (proliferation, migration) to promote endothelial cell 
activation.  Elevated ET1 signaling can thus contribute to endothelial dysfunction 
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Supplemental Material and Methods  
 
Diabetic mice  
Female mice (C57Bl6/J purchased from Jackson Laboratories or Rasgrp3gt/gt 
mice backcrossed to N8 on the C57Bl6/J background) at 6-8 weeks of age were 
made diabetic following the protocol in “Animal Models of Diabetic Complications 
Consortium”.  Mice were fasted and injected IP with streptozotocin (STZ) (stored 
at -20°C and dissolved to a final concentration of 7.5 mg/mL in 0.1M Na-Citrate 
buffer (pH 4.5) immediately prior to injection), at a dose of 50 mg STZ/kg of body 
weight, daily for 5 days.  Controls were injected with citrate buffer alone.  
Alternatively, Ins2Akita/+ mice on the C57Bl6/J background (Jackson Laboratories) 
were bred to obtain Ins2Akita/+; Rasgrp3gt/gt mice.  Blood glucose was monitored 
weekly using a OneTouch Ultra device and a drop of blood from a tail nick.  Mice 
were considered diabetic with blood glucose levels over 250mg/dL.  Most mice 
were diabetic 2-3 weeks after the last injection and remained diabetic long-term.  
Mice were mated to genotype-matched males.    
 
Embryo and yolk sac analysis  
Embryos were harvested at E9.5, fixed in fresh 4% PFA (paraformaldehyde) 
overnight at 4oC, and whole mount stained for PECAM as described 1.  Briefly, 
embryos were washed 15 min in PBS, dehydrated through a methanol:PBS 
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series, blocked in 5% H2O2/methanol 4 hr at RT, then stored overnight in 100% 
methanol at -20°C.  They were rehydrated through a methanol:PBS series, 
blocked 2 x 1 hr in PBT (0.2%BSA, 0.1% Triton X-100 in PBS), incubated 
overnight at 4°C in 1:200 rat anti-mouse CD-31 (PECAM) primary antibody (BD 
Biosciences) in PBT, rinsed 5 x 1hr in PBT and incubated overnight at 4°C in 
1:200 goat anti-rat HRP-conjugated secondary antibody (Kirkegaard & Perry, cat. 
#474-1612) in PBT.  Embryos were rinsed 5 x 1hr in PBT, then developed for 20 
min at RT in DAB solution (Vector Laboratories, cat. #SK-4100).  After 
developing, embryos were rinsed 2 x 5 min in PBT, 2 x 5 min in PBS, and fixed 
overnight at 4°C in 2% PFA/0.1% glutaraldehyde in PBS.  Embryos were rinsed 3 
x 5 min in PBS, then stored in PBS at 4°C.  Stained embryos were imaged with 
an Olympus SZH10 stereo microscope outfitted with a with a Olympus DP71 
camera.  Embryos were scored for developmental defects on a scale of 0-3, and 
defects included aberrant intersomitic vessels, lack of neural tube closure, 
perturbed somite patterning, lack of remodeling and excessive vessel coverage 
in the head plexus, gaps or excessive vessels dorsal to the somites, and overall 
body-axis deformities.  Embryos with no defects were scored 0; embryos with a 
single minor defect were scored 1; embryos with several defects were scored 2; 
and embryos with the most comprehensive and severe defects were scored 3. 
Yolk sacs were removed from the embryos after the rehydration step, and 
stained separately for PECAM as described 2 with minor modifications.  Briefly, 
yolk sacs were blocked in 5% goat serum, 1% BSA in PBST (PBS with 0.1% 
Triton 100X) overnight at 4°C, and then incubated in primary antibody (PECAM 
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CD31, BD Pharmingen #557355, rat anti-mouse) at 1:200 in PBST overnight at 
4°C.  Yolk sacs were washed in SBT (PBS with 0.1% Triton 100X and 2.5% goat 
serum), 4 times over at least 4 hr. Yolk sacs were then incubated in secondary 
antibody (Alexa Fluor 488, Molecular Probes #A-11006, goat anti-rat) overnight 
at 4°C and washed in SBT 4 times over at least 5 hr, and finally washed in PBS.  
Yolk sacs were then mounted flat on glass slides with Vectashield Hardest and 
allowed to harden, then imaged using an Olympus IX 50 Epifluorescence 
microscope.  
  
Whole embryo culture 
Whole embryo culture was performed as described, with minor modifications 
3.  Embryos were dissected into M2 media from maternal decidua with their yolk 
sacs intact.  Dissections were performed at E7.5 (for PMA experiments) or E8.5 
(for glucose experiments), and embryos were cultured for 24 hr in 25 mL Nunc 
screwcap tubes on rollers at 37°C.  Culture media contained 50% rat serum, 50% 
Tyrode’s salt solution, and 0.1X penicillin/streptomycin and was sterile filtered 
using a 0.2 µM filter.  A minimum of 0.75 mL of media was used per embryo.  
During culture, the media was treated at 12-hr intervals with a gas mixture 
containing 20% O2 and 5% CO2 and the tubes were sealed with vacuum grease.  
Some embryos were treated with 50nM PMA (phorbol 12-myristate 13-acetate) 
and some had 20 mM D-glucose added to the media during the culture period.  




RasGRP3 was amplified by PCR cloning from with appropriate restriction 
sites at the ends, cloned into pBSIISK+/CAAX vector (kindly provided by Dr. 
Channing Der), and verified by sequence analysis.  This version was shuttled 
into pEGFP-C1 (Clonetech, Genbank #U55763) so that eGFP was linked to the 
N-terminus of RasGRP3-CAAX, and expression was from the CMV promoter.  
GFP-RasGRP3 was generated by excision of the CAAX domain using Hind III 
sites. 
HUVEC (purchased from Clonetics) were cultured in EGM-2 medium (Lonza) 
on gelatin-coated dishes and used between passages 2-8.  1 x 106 cells in 
HUVEC optimized buffer (Amaxa) were transfected with 5 mg DNA using a 
nucleofector (Amaxa, #VPB-1492) and HUVEC optimized kit, according to 
manufacturer’s directions.  Fresh medium was added 2 hr post-transfection. 
For staining, transfected HUVEC were plated in 4-chamber slides, and 48 hr 
post-transfection starved for 6 hr in HUVEC medium with 0.1% FBS and no 
growth factors.  Cells were fixed in 3.7% formaldehyde for 12 min, permeabilized 
in PBS/0.1% Triton for 5 min, blocked in PBS/1% BSA for 20 min, and incubated 
with phalloidin-Alexa 555 (Molecular Probes) diluted 1:50 in blocking buffer for 20 
min.  Fixation and staining was at RT. 
Migration assays were done with HUVEC at 48 hr post-transfection.  Cells in 
slide flasks were labeled with Cell tracker Red (Molecular Probes), and imaged in 
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green and red channels over a 5 hr period with a Nikon TE300 Inverted 
Microscope (Melville NY) with a Perkin Elmer spinning disc confocal head 
(Shelton CT) and outfitted with a heated stage.  Images were collected at 1 min 
intervals using Metamorph software (version 6.3r5; Universal Imaging Corp, 
Downington PA) and a Hamamatsu Orca CCD camera (McHenry IL).  Average 
velocity and distance to origin of cells was calculated using trajectory measures 
as diagrammed in Figure 2.3 J.  
Mouse endothelial cells 
Mouse endothelial cells (wildtype and Rasgrp3gt/gt) were generated and 
expanded as described 4, 5, with minor modifications.  Lungs of P6 wildtype (WT) 
and Rasgrp3gt/gt mice were minced and digested with collagenase (Type 1, 
#CLS-1, Worthington, Lakewood NJ), diluted to 2 mg/ml in PBS containing Ca++ 
and Mg++, for 1 hr at 370C, and, then incubated with magnetic beads conjugated 
to anti-mouse PECAM antibody for 20 min at RT.  Bead-selected cells were 
incubated with PyMT virus (2.5 x 107 cfu/ml, cells a gift of Dr. William Sessa) and 
8 mg/ml polybrene diluted in complete EBM-2 medium (Bullet kit, Lonza CA) for 8 
hr/day for 3 days; cells were allowed to recover in complete EBM-2 medium 
overnight between virus incubations. Following incubation, cells were treated with 
500 mg/ml Geneticin (G418, CalBiochem) for 14 days.  Drug-resistant clones 
were isolated using cloning rings and expanded.  Cells were maintained in 
complete EBM-2 media and incubated at 37oC in 5% CO2.  Growth curves were 
generated by plating 5 x 103 cells/well, and trypsinized cells were counted daily 
using a hemocytometer. 
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Cells were washed in 1X PBS, fixed with 1:1 cold methanol-acetone or 4% 
paraformaldehyde (PFA) for 10 min, washed twice in 1X PBS, then blocked with 
staining media (3% FBS, 0.1% sodium azide in 1X PBS) for 1 hr at 37ºC. Cells 
were incubated in appropriate primary antibodies at 1:1000 in staining media 
overnight at 4ºC.  Primary antibodies used were rat anti-mouse PECAM 
(MEC13.3, #553370, BD Biosciences), rat anti-mouse ICAM-2 (CD102, #553326, 
BD Biosciences,), rat anti-mouse VE-cadherin (CD144, #550548, BD 
Biosciences), and rabbit anti-phospho-histone H3 (Ser10, #06-570, Millipore).  
Cultures were washed 2 X in 1X PBS, incubated in AlexaFluor488 goat anti-rat 
IgG (1:1000) or Alexa Fluor 594 donkey anti-rabbit IgG (#A21206, Invitrogen) 
diluted in staining media for 2 hr at RT, washed 2 X in 1X PBS and imaged using 
an inverted epifluorescence microscope (IX-50; Olympus) outfitted with a camera 
(DP71; Olympus), or a confocal microscope (LSM 5 Pascal, Carl Zeiss, Inc.) 
using PASCAL Release version 4.2 SP1 acquisition software (Carl Zeiss, Inc.).  
Endothelial cells were harvested and RNA isolated using Trizol (Invitrogen). 
RNA was purified using the RNAeasy kit (Qiagen), and cDNA was generated as 
described 6. Equivalent amounts of cDNA were amplified by RT-PCR using 
RasGRP3 primers (forward 5’-AGAGAACCACTGCCTCGTAC-3’; reverse 5’-
GTGTTGCCGCTT TCCCGAGC-3’) and lacZ primers (forward 5’-
TTGAAAATGGTCTGCTGCTG-3’; reverse 5’-TTGGCTTCATCCACCACATA-3’) 
as described 7. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers 
(forward 5’-AGCCCATCACCATCTTCC-3’; reverse 5’-
GCCATCCACAGTCTTCTGG-3’) were used as a control.  
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For mitotic index determination, cells were plated at 2.5 x 104 cells in 
chamber slides, serum-starved in 1% FBS overnight, then stimulated with 100nM 
ET1 in 1% FBS for 24 hr. Cells were fixed with 1:1 methanol: acetone and 
stained for PECAM and PH3 as described.  Ten images from each sample were 
taken at 10X magnification, and the mitotic index was calculated by counting the 
number of PH3-positive cells divided by the PECAM-positive cells.  For migration 
assays, Boyden chambers were used as described 8, with minor modifications.  
Transwell chambers fitted with 8-µm pore size filter membranes (Corning 
Incorporated, Corning NY) were immersed in medium.  Cell suspensions were 
prepared in 1% FBS, and 2 x 104 cells in 100 µl were plated in the upper 
chamber.  Cells were incubated overnight at 37˚C, then incubated with 600 µl of 
1% FBS containing 2.5 nM VEGF-A, or 100 nM ET1, placed in the bottom of 
each transwell chamber for 6 hr at 37˚C. Cells on the upper surface of the filter 
were removed, and cells on the bottom surface of the filter were fixed and 
stained with Hema 3 stain (#122-911, Fisher, Pittsburgh PA).  Migration was 
quantified by counting the total number of cells in 10 fields per chamber at 20X 
magnification using an Olympus IX-50 epifluorescence microscope attached to a 
camera. 
ES cell differentiation  
Wild type (WT, +/+) and RasGRP3 deficient (Rasgrp3gt/gt, where gt represents a 
gene trap insertion in the RasGRP3 locus that results in a loss-of-function 
mutation 7) ES cells were maintained and differentiated in vitro as previously 
described 9. For inhibitor studies, wild type ES cell cultures were differentiated to 
   124 
day 7, and then pre-treated with the appropriate inhibitor for 2 hr prior to PMA 
(phorbol 12-myristate 13-acetate) addition.  Cultures were stimulated with 100 nM 
PMA for 24 hr, and then fixed with 1:1 methanol/acetone and stored in PBS at 
4oC.  Unless otherwise stated, inhibitors remained on the ES cell cultures for the 
duration of PMA treatment.  Dose curves ranging from 1 mM to 20 mM were 
performed, and the most effective concentration that maintained wild-type vessels 
was used.  Inhibitor concentrations used were: FTI-2153 (farnesyl transferase 
inhibitor) at 10 mM, U0126 (MEK inhibitor) at 10 mM, SB203580 (p38 MAPK 
inhibitor) at 5 mM, SP600125 (JNK inhibitor) at 10 mM, Bisindolymalemide I (BIM; 
general PKC inhibitor) at 10 mM, Gö6976 (PKCα and PKCβ inhibitor) at 6 mM, 
and rottlerin (PKCδ inhibitor) at 10 mM.  Inhibitors were purchased from 
Calbiochem (San Diego, CA).  For ET1 studies, ES cultures were treated with 
fresh medium containing 100 nM ET1 daily on days 5-8, then fixed with 1:1 
methanol:acetone and stored in PBS at 4oC. 
 
Antibody staining   
Antibody staining of ES cell cultures was as previously described 1, 9.  Briefly, 
fixed ES cell cultures were blocked in staining media (3% fetal bovine serum and 
1% sodium azide in 1X PBS) for 1 hr at 37ºC.  Cultures were then incubated with 
rat anti-mouse PECAM (Mec 13.3; BD Pharmingen, San Diego, CA) at 1:1000 in 
staining media for 1 hr at 37ºC and subsequently washed 3 times with staining 
media.  The cultures were incubated with goat anti-rat Alexa 488 (Molecular 
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Probes, Eugene, OR) at 1:200 for 1 hr at 37ºC, rinsed in staining medium 3 times, 
then stored in 1X PBS at 4ºC.  Staining was visualized using either an Olympus 
IX-50 inverted microscope and epifluorescence, or a Zeiss 510 confocal 
microscope. 
 
Quantitative image analysis   
Quantitative image analysis of PECAM-stained day 8 ES cell cultures was 
performed as previously described 1.  Briefly, 10X images of non-overlapping 
areas with complete cell coverage were acquired.  In general, the imaged area of 
each well was more than 60% of the total area.  Images were analyzed using 
Metamorph software to determine the percent area of PECAM staining normalized 
to controls.  On average, three to four wells of each condition were used for 
analysis. All values were compared by the two-tailed Student’s T test, and p 
values <0.05 were considered significant.  
  
Ras and ERK activation assays 
Ras and ERK activation assays were performed as described, with minor 
modifications 10, 11.  HUVEC were grown to near confluency for 48 hr after 
transfection (50-80% transfected by GFP labeling), serum starved as described 
overnight, then put in lysis buffer (50 mM Tris (pH 7.4), 0.15 M NaCl, 1% Triton, 
10% glycerol, 1 mM EDTA, 10mM MgCl2) with protease inhibitors.  Mouse 
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endothelial cells were grown to 60% confluence, serum-starved in 0.1% 
FBS/EBM-2 media overnight, then left untreated or treated with 100 nM PMA, 5 
nM VEGF-A, or 100 nM ET1 diluted in 0.1% FBS/EBM-2 medium for 30 min 
(PMA) or 5 min (VEGF-A, ET1) prior to lysis.  Ras activation assays were 
performed using the Ras Activation Assay Kit (Upstate, Lake Placid, NY) per 
manufacturer’s protocol, and 10% of the lysate was used for total Ras 
determination.  The remaining lysate was incubated with 10 ml of agarose beads 
conjugated to the Ras binding domain of Raf (RBD) for 1 hr at 4ºC, briefly 
centrifuged to pellet the beads, then washed with lysis buffer.  Samples were 
suspended in 50 ml of 2X sample buffer and boiled for 5 min before loading on a 
15% acrylamide gel for electrophoresis.  Proteins were transferred to a PVDF 
membrane, blocked in 5% milk in 1X TBST (Tris-Buffered Saline with 0.1% 
Tween), and incubated with mouse monoclonal anti-Ras antibody (Clone Ras10, 
Upstate) at 1:1000 in blocking solution overnight at 4ºC.  After washing 3 times for 
15 min, the membrane was incubated for 2 hr at RT with a goat anti-mouse 
secondary antibody conjugated to HRP (Upstate) at 1:5000 in blocking solution.  
After washing, the membrane was developed using ECL Plus according to the 
manufacturer’s instructions.   
For phospho-ERK blots, most conditions were the same as for Ras assays, 
except cells were lysed in RIPA buffer and loaded on a 10% acrylamide gel.  
Primary antibody incubation was with rabbit anti-mouse pERK (Cell Signaling) at 
1:1000 overnight at 4ºC, and total ERK was determined by incubation with mouse 
anti-mouse ERK1/2 (Abcam) at 1:1000 overnight at 4ºC.  Secondary antibody 
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incubation was with goat anti-rabbit HRP or goat anti-mouse HRP (Promega) at 
1:5000 for 2 hr at RT.  Blots were quantified using the integrated density function 
of ImageJ (Version 1.44a, NIH, USA) or a phosphoimager (Storm 840, Molecular 
Dynamics, Sunnyvale CA).  Ras-GTP was first normalized to total Ras, then 
normalized to untransfected WT HUVEC.  pERK intensities were divided by total 
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